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ABSTRACT

Qing, Kurt Y. Ph.D., Purdue University, May 2015. Optimizing the Neural Response to
Electrical Stimulation and Exploring New Applications of Neurostimulation. Major
Professor: Pedro Irazoqui.

Electrical stimulation has been successful in treating patients who suffer from neurologic
and neuropsychiatric disorders that are resistant to standard treatments. For deep brain
stimulation (DBS), its official approved use has been limited to mainly motor disorders,
such as Parkinson’s disease and essential tremor. Alcohol use disorder, and addictive
disorders in general, is a prevalent condition that is difficult to treat long-term. To
determine whether DBS can reduce alcohol drinking in animals, voluntary alcohol
consumption of alcohol-preferring rats before, during, and after stimulation of the
nucleus accumbens shell were compared. Intake levels in the low stimulus intensity
group (n=3, 100μA current) decreased by as much as 43% during stimulation, but the
effect did not persist. In the high stimulus intensity group (n=4, 200μA current), alcohol
intake decreased as much as 59%, and the effect was sustained. These results demonstrate
the potent, reversible effects of DBS.

Left vagus nerve stimulation (VNS) is approved for treating epilepsy and depression.
However, the standard method of determining stimulus parameters is imprecise, and the
patient responses are highly variable. I developed a method of designing custom stimulus

xii
waveforms and assessing the nerve response to optimize stimulation selectivity and
efficiency. VNS experiments were performed in rats aiming to increase the selectivity of
slow nerve fibers while assessing activation efficiency. When producing 50% of maximal
activation of slow fibers, customized stimuli were able to activate as low as 12.8% of fast
fibers, while the lowest for standard rectangular waveforms was 35.0% (n=4-6 animals).
However, the stimulus with the highest selectivity requires 19.6nC of charge per stimulus
phase, while the rectangular stimulus required only 13.2nC.

Right VNS is currently under clinical investigation for preventing sudden unexpected
death in epilepsy and for treating heart failure. Activation of the right vagal
parasympathetic fibers led to waveform-independent reductions in heart rate, ejection
ratio, and stroke volume. Customized stimulus design with response feedback produces
reproducible and predictable patterns of nerve activation and physiological effects, which
will lead to more consistent patient responses.
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CHAPTER 1. INTRODUCTION TO ELECTRICAL STIMULATION

1.1

Medical Uses of Electrical Stimulation

Many neurologic and neuropsychiatric disorders have no cure. Even for disorders
that have established behavioral and pharmacological treatments, a significant amount of
patients respond poorly and inconsistently. Parkinson’s disease1–3, epilepsy4,5,
neuropathic pain6,7, alcoholism8–10, and depression11,12 are a few examples. Some
conditions, such as neurological blindness and deafness, have no pharmacological
treatments. These disorders and disabilities can be debilitating and pose high burdens on
healthcare and society13,14.
Electrical stimulation offers a safe and effective treatment for these conditions.
Neuroprosthetics, with cochlear implants, vagal nerve stimulators (VNS), and deep brain
stimulators (DBS) being the prominent examples, are now well known and common
treatment options. Cochlear implants have been very successful in restoring hearing.
However, because cochlear stimulation tends to be in a field by itself, it will not be
discussed in detail. VNS has been FDA-approved for use in epilepsy and depression15,
and DBS has been approved for treating Parkinson’s disease, essential tremor, and
dystonia16. In addition, there are strong indications for other applications of VNS and
DBS15,16, where many more patients can receive much needed therapeutic benefits.
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To deliver effective treatments, the electrical stimulus must be both
therapeutically efficacious and safe. For both VNS and DBS, overall efficacy has been
solidly established, but patient response is highly variable. Also, modern stimulators are
still plagued by side effects and complications, which are largely due to lack of
selectivity and somewhat due to limited battery life, respectively16–19. Side effects differ
among patients as well and can limit efficacy. Therefore, increasing the selectivity of
stimulation and prolonging battery life can increase the effectiveness of treatment.
As our understanding of the field improves, and as efforts continue to solve the
major challenges, the technology has been evolving steadily, and the scope is becoming
increasingly vast. The major aims of my thesis work were 1) to explore new areas to
apply electrical stimulation and 2) to improve the current stimulation paradigm by
introducing a new method of designing stimulus waveforms and analyzing the effects. In
this first chapter, I review the key advances in the field of electrical stimulation and
describe the current paradigm. This introduction chapter establishes the foundation and
rationale for the experiments that follow.

1.2

Historical Advances in Stimulation Paradigms

To improve electrical stimulation therapy, refining stimulus design is the key.
With more than two centuries of laboratory research and clinical studies, there exists
abundant knowledge regarding how neural tissue responds to different stimuli.
Guillaume Duchenne, in his book A Treatise on Localized Electrization20,
attributed the first documented therapeutic uses of electricity to Kruger d'Helmstadt in
1744. These initial attempts utilized static electricity, the only available form of
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electricity at the time, and involved devices such as Leyden jars, which stored and
discharged static charge. This method is poorly controlled, has questionable efficacy, and
can be dangerous. Fortunately, over time, both technique and understanding of electrical
stimulation improved dramatically.
First came direct current (DC) stimuli, mostly resulting from the Galvani-Volta
debates at the end of the 18th century20–22. Then in early 1800’s, due to the birth of
electromagnetism, alternating currents (AC) became available. The constant push and
pull of electrical charge made it superior to DC stimuli20, but the push-pull also led to a
lack of charge buildup in tissue, and efficacy is still low23. Indeed, even among modern
waveforms, the biphasic charge-balanced pulse without delay, which resembles an AC
waveform, is comparatively not so efficacious24–26.
Batteries (voltaic cells) alone can only produce DC stimuli, but with a switch for
completing and breaking the circuit, experimenters were able to produce interrupted DC
waveforms. Using such waveforms, Emil du Bois-Reymond found that the response is
much higher than DC and AC waveforms22. Circa 1850, he established the “general law
of excitation of nerves”, which states that nerve activation is due to changes in current
amplitude and not the exact amplitude22.
At about the same time, Eduard Pflüger introduced his “law of contraction”27. In
addition to supporting du Bois-Reymond’s law of excitation, Pflüger’s experiments also
resulted in two important findings. The first is that excitation originates at the cathode,
not the anode, upon making the circuit (this point will be discussed further in Subsection
1.3.5). Pflüger’s second finding is that when breaking the circuit, excitation can occur at
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the anode. This “anode break excitation” has since been well-characterized28,29 and is
regarded as an unintended effect that is to be avoided30,31,32.
At the start of the 20th century, the monumental works of Georges Weiss and
Louis Lapicque formed the foundation of modern electrical stimulation (their findings are
discussed in Subsection 1.3.2)23,33–35. Their experiments contributed to a new paradigm
that is still the standard today—pulsatile stimulation, where waveforms are constructed
using brief pulses with defined parameters, such as pulse width and amplitude. Compared
to interrupted DC waveforms, pulse waveforms have a much lower duty cycle but are
still effective at activating excitable tissue.
As a safer variant of simple pulsatile waveforms (monophasic), John Lilly and
colleagues presented the biphasic pulse waveform (sometimes referred to as the Lilly
waveform)36. Termed “zero net flow” by Lilly, these biphasic waveforms are now widely
used, though monophasic pulses are commonly used as well. A comparison is provided in
Subsection 1.3.6.
After Lilly’s modification, there have been no major advances in stimulation
paradigms. Not much has changed since the time of Weiss and Lapicque, over a century
ago. However, the collective understanding of the mechanisms of electrical stimulation
and the relationships between the stimulus and physiological response has increased
substantially. The next section will synthesize key early discoveries reviewed above and
some of the major concepts established more recently. These principles are important for
understanding the modern stimulation paradigm and for exploring new paradigms.
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1.3

Core Principles of Electrical Stimulation

1.3.1

The Electrode-Tissue Interface

Electrical stimulation acts by driving currents through tissue, which includes
neurons, glia, and extracellular matrix. Delivering current into target tissue requires the
use of electrodes. The study of electrodes is a vast field in itself, so only basic principles
relevant to stimulus design will be discussed here. A thorough analysis of the
electrochemistry of electrodes can be found in the well-known book by Bard and
Faulkner37. An article by Stuart Cogan38 also offers a good review of electrode properties
and design.
Many electrode designs and configurations exist, including monopolar, bipolar,
cuff, concentric, tripolar, etc. For simplicity, the analysis here will focus on the
monopolar configuration, in which a single electrode serves as the working electrode
while a second electrode serves as both the counter and reference. In this case, if this
second electrode is implanted in distant tissue that is not of interest, its effects can
essentially be ignored.
When a voltage is applied across the working and counter electrodes, it drives a
current between the electrodes and through tissue. With an ideal non-polarizable
electrode, the stimulus current readily drives faradaic reactions at the electrode-tissue
interface—electrons will be transferred across the interface via oxidation-reduction32,37,38.
Significant faradaic reactions can damage both electrode and tissue.
In contrast, with an ideal polarizable electrode, electrons cannot cross the
interface. Instead, the applied current will cause charged molecules and ions to form what
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is termed the “double layer” at the interface, which behaves like a capacitor37. A more
detailed description of the double layer can be found in Chapters 1, 10, and 13 of the
Bard-Faulkner book37.
The electrochemical behavior of the stimulating electrode, target tissue, and the
interface can be approximated as an electrical equivalent circuit. While many circuit
models exist, this document will focus on the famous Randles model39, shown in Figure
1. This model also applies to the counter and reference electrodes.

Figure 1 The Randles equivalent circuit model for the electrode-tissue interface.
Please see text for description and explanation. The figure is created based on
Randles’s original work39.
Re is the resistance of the electrode material; the impedance due to Re tends to be
negligible relative to that of other components. Zm denotes the passive impedance of the
medium, which is a conductive solution or tissue. In a solution, Zm is purely resistive,
but in tissue, Zm is complex. The Rf and Cf terms represent, respectively, the resistive
and capacitive behavior of faradaic charge transfer at the interface. These two terms
collectively form the faradaic impedance, Zf. Cdl represents the double layer capacitance.
Each component of this circuit model is associated with a physical phenomenon
and can be used to infer characteristics of the electrode and tissue. Zf and Cdl are
particularly important. For example, a highly polarizable electrode with high Zf and large
Cdl is great for stimulation. The significance of a large Cdl is that, given a voltage, more
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charge can be injected into the double layer. A high Zf allows the electrode to sustain
higher voltages without undergoing significant faradaic reaction. Zm is also important.
For chronic implants, Zm typically increases over time, which is attributed to tissue
encapsulation. Tissue encapsulation is an innate response and adversely affects
treatment40–43.
To determine these circuit components for a particular system, electrochemical
impedance spectroscopy (EIS) is commonly performed38,41,44,45. EIS builds the voltagecurrent relationship of the system by measuring the impedance to sinusoidal voltage
signals over a large range of frequencies. The impedance data then can be used to
construct a circuit model with quantified component values. EIS theory is discussed in
detail in Chapter 10 of the Bard-Faulkner book37 and by Andrzej Lasia46.
The properties of the electrode-tissue interface create major limits for stimulus
design and the device. For example, smaller stimulating electrodes can be more regionspecific but have smaller Cdl. A small Cdl results in higher impedance, which increases
the stimulator voltage required to deliver the same therapeutic level of current and the
overall power consumption.

1.3.2

Strength-Duration Relationships

Georges Weiss developed instruments to generate brief, voltage-controlled
rectangular pulses, of which both the pulse width and voltage amplitude can be precisely
adjusted. Using this pulsatile stimulation, he built a mathematical model that relates nerve
responses to stimulus parameters. In 1901, he proposed the following formula:
Q = a + bt

Equation 1
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where “t” is the pulse width (duration) and “Q” the product of the threshold voltage
amplitude for nerve activation and pulse width33,34. “a” and “b” are merely empirical
constants used to fit the data to a linear regression model. Today, “Q” is defined as the
product of threshold current and pulse width, which for rectangular pulses, is the charge
injected by the pulse.
In a follow-up article in 19091, Louis Lapicque expanded upon Weiss’s model
and defined the terms “rheobase” (“rhéobase” in French) and “chronaxie”35. The
rheobase is the theoretical minimum pulse voltage required to activate a nerve using an
infinite pulse width. The chronaxie is the pulse width required to activate a nerve when
using a pulse voltage twice the rheobase. Again, today, these concepts are described
using current amplitudes.
The relationships described by Weiss and Lapicque are now known as the
strength-duration relationships (Figure 2). The strength-duration equations, written
below, relate the threshold current (Ith), threshold charge (Qth), and threshold energy (Eth)
required for nerve activation to pulse width (t), rheobase (Ir), and chronaxie (tc)34,47,48.
For energy, a constant resistance (R) is assumed.
𝑡

𝐼𝑡ℎ = 𝐼𝑟 ( 𝑡𝑐 + 1)

Equation 2

𝑄𝑡ℎ = 𝐼𝑡ℎ ∗ 𝑡 = 𝐼𝑟 𝑡𝑐 + 𝐼𝑟 𝑡

Equation 3

𝑡

2
𝐸𝑡ℎ = 𝐼𝑡ℎ
∗ 𝑅 ∗ 𝑡 = 𝐼𝑟2 𝑅 𝑡 ( 𝑡𝑐 + 1)2

1

Equation 4

This article is actually located in Comptes Rendus Soc Bio. The article is sometimes wrongly cited as
Comptes Rendus Acad. Sci. Lapicque did publish an article in the same year there, but it was not the one
where he introduced the concepts of rheobase and chronaxie.
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Figure 2 Strength-duration curves. The black dashed line illustrates Equation 2.
The black dotted line illustrates Equation 3. The black solid line illustrates Equation
4. The rheobase current is set to an arbitrary value of 1, and so is the chronaxie. All
values on the axes are therefore relative to the rheobase (gray solid line) and chronaxie
(gray dashed line). For Equation 4, R is also set to 1.
These equations do not perfectly fit empirical data but are close approximations;
reported r2 is usually > 0.9948–50. It is important to note that, for pulse shapes other than
rectangular, the current-duration relationship still holds true, but the average, not the peak,
current should be used for analysis34. Also, it is interesting to note that, though Weiss and
Lapicque used voltage-controlled stimuli in their experiments, they presented their
models in terms of I and Q.
The strength-duration equations and curves illustrate clearly the importance of
pulse width in determining efficacy:
1.

The longer the pulse width is, the lower the threshold current is.

2.

The shorter the pulse width is, the less the threshold charge is.

3.

At the chronaxie, the lowest energy is needed.
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While strength-duration relationships were first created for studying nerve
activation, these principles certainly can be applied to brain stimulation as well. Charles
Gallistel and colleagues published a series of articles in the 1970s that characterized the
relationship between stimulus pulse width and the charge required to elicit rewardseeking behavior in rats51–53. Though the data tend to deviate more from the models, the
general relationship does hold true. Other laboratory54,55 and clinical56,57 studies also
agree with this finding.

1.3.3

Current-Distance Relationship

When driving currents using electrodes, a voltage profile that is dependent on
tissue impedance develops in tissue (good illustrations of such voltage profiles can be
found in 58–61). Therefore, a relationship exists between threshold current and distance of
a neuron from the electrode, which takes on a parabolic shape, with threshold current
increasing with increasing distance62. The existence of such a relationship is easy to
appreciate, and the concept is rather intuitive. Thus, the details of the current-distance
relationship will not be discussed further here. A 1996 article by Edward Tehovnik63
offers a good review of this principle.
This relationship is very important in brain stimulation, where, less so for nerves,
tissue organization and function vary highly with respect to space. So, when stimulating a
specific region, much of the neural tissue near the electrode will be activated, leading to
the therapeutic effect. However, a portion of the tissue surrounding the target region will
be activated as well, leading to side effects. Ensuring adequate stimulation of the target
region while minimizing activation of the neighboring tissue is very difficult.
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1.3.4

Electrical Properties of the Neuron

Neurons respond to electrical stimuli by changing their membrane properties.
Activating a neuron is simply inducing an action potential. The renowned HodgkinHuxley study28 essentially created an equivalent circuit that describes the behavior of
neuron membranes to an applied current (see Figure 3 for a simplified model).
The mechanism of the action potential lies in
the dynamics of the channel conductances. The
membrane voltage is a function of the Nernst
potentials and conductances of the many types of ion
channels28,64. The Nernst potentials are fairly constant,
but the conductance of each channel type varies
differently with membrane voltage and time. If the
resting membrane is depolarized past the threshold
voltage, due to a natural or artificial stimulus, changes
in conductances are initiated, resulting in the action
potential28.
Though the Hodgkin-Huxley model was built
for the isolated axon, similar models can be built for
the neurons of the central nervous system. These
models can be used to study and predict how different
axon fiber populations58,65–67 and different
compartments of the neuron, such as dendrites and
somata68–70, respond to electrical stimuli.

Figure 3 Simplified
Hodgkin-Huxley model. Vo
and Vi denote the potentials
on the outside and inside of
the membrane, respectively.
Cm models the membrane’s
capacitive behavior. Em
represents the membrane
voltage, and gm is the
membrane conductance
lumped from all the channels
(note g = 1/resistance). By
modern convention, Em =
Vi - Vo, and the current I is
positive flowing from inside
to outside. Modified from
Hodgkin and Huxley28.
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1.3.5

Cathodic versus Anodic Stimulation

Based on the Hodgkin-Huxley model and its conventions, the membrane is
negatively polarized at rest, meaning there is an excess of negative charge on the inside.
If an outward current is induced, it will depolarize the membrane, and vice-versa28,71. To
produce an outward current, the working electrode is driven to a negative potential,
termed cathodic stimulation. Negative charge then accumulates near the extracellular side
of the membrane, leading to depolarization, which subsequently can initiate an action
potential. Note that in electrical stimulation, the intracellular compartment is not directly
manipulated.
On the other hand, when the working electrode is driven to a positive potential—
anodic stimulation—positively charged ions will accumulate, leading to
hyperpolarization. However, anodic stimulation can still elicit action potentials in nerves
or axons via the creation of what Merrill et al. referred to as a “virtual cathode”32, which
is a relative cathodic field that surrounds the applied anodic field 58,71,72. These virtual
cathodes are weaker in amplitude than a directly applied cathodic field, and so the
expected efficacy is lower as well.
Indeed, for neuronal activation, modeling58,65,66 and empirical evidence73,74 both
suggest that cathodic pulses are more efficacious75. For DBS, results from laboratory54
and clinical studies76 also support the use of cathodic pulses.
For cortical stimulation, when using penetrating electrodes, like those used in
DBS studies, cathodic stimulation is also more efficacious62,77,78. However, when using
surface electrodes to stimulate the cortex, researchers have shown that anodic stimulation
can be more efficacious in regions with high corticofugal output75,79,80. Due to the
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current-distance relationship, it is difficult to activate deeper axon-rich layers with
cathodic pulses from the surface. In this case, to target the axon-rich layers, anodic
stimulation can be used to create virtual cathodes deeper in the cortical tissue.

1.3.6

Monophasic versus Biphasic Stimulation

As mentioned earlier, biphasic waveforms are used mostly for safety reasons. By
principle discussed previously, biphasic waveforms usually are cathode leading. The
initial cathodic pulse is intended to depolarize the neurons, eliciting action potentials. The
charge injected by the cathodic pulse is then reversed by the anodic pulse that follows, so
that there is no potential buildup that could lead to faradaic reactions. Cathode leading
has been shown to yield lower threshold currents in nerve stimulation25 and cortical
stimulation78.
Though there is disagreement81,82, overwhelming evidence suggests that biphasic
stimuli are indeed safer15,80. The tradeoff, however, is that biphasic waveforms are less
efficacious, with the delay between cathodic and anodic pulses being an important
factor24–26.

1.3.7

Current- versus Voltage-Controlled Stimulation

Whereas all articles up to Weiss’s and Lapicque’s time described using voltagecontrolled stimuli, as early as Penfield’s homunculus experiments, experimenters began
to report that current-controlled stimuli tend to be more consistent and effective85,86.
Today, overall, current-control is the standard. In this paper, “current-control” refers to
applying a current of defined amplitude between the working and counter electrodes, and
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“voltage-control” refers to applying a defined voltage across the working and counter
electrodes.
The major disadvantage of using voltage-controlled stimuli is that only the
voltage between the working and counter electrodes is controlled32. At the pulse onset,
when the capacitive components of the electrode and tissue are not charged, the current is
high, but as they charge, the current will decrease. In addition, because the electrode and
tissue impedances are both variable over space and with time, the voltage profile through
the tissue is inconsistent.
Based on these observations, from an efficacy perspective, voltage-control offers
poor reproducibility32. Indeed, modeling has shown that, with voltage-controlled stimuli,
the volume of tissue activation and the voltage profile are highly dependent on electrode
and tissue capacitances87. In a recent investigation, Lempka et al. have shown that
voltage-controlled stimulation causes significantly larger variability in the voltage
recorded from recording electrodes near the DBS electrode88. And from a safety
perspective, though the voltage is set, electrode potentials can drift over time with
repeated stimuli, especially with high frequency pulses, which leads to undesirable
faradaic reactions32,81,82.
Voltage-control is mainly seen in DBS, where the voltage amplitude requires
constant readjustment89–92. Recently, this DBS paradigm has been called into question93.
Laboratory experiments88,94 and randomized clinical trials95 have shown that currentcontrolled DBS yields more consistent results, and voltage-controlled DBS may soon
become obsolete.
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1.4

Modern Stimulation Paradigms

The standard modern stimulus waveform is composed of a train of repeating pulse
waveforms. Important parameters regarding each pulse are listed below:


Pulse shape – examples include rectangular, triangle, and sinusoid



Amplitude (AMP) – amplitude of the pulse, either voltage or current



Pulse width (PW) – the duration (a time value) of each pulse

Though many pulse shapes have been proposed and studied96–99, the rectangle is
still the most common shape used in research and clinical settings. Used since the time of
Weiss and Lapicque, it is popular due to its ease in implementation and mathematical
simplicity.
A pulse train then can be formed using single pulses—monophasic—or biphasic
pulse waveforms. Important biphasic pulse parameters are:


Cathodic amplitude – amplitude (either voltage or current) of the cathodic

pulse


Anodic amplitude – amplitude of the anodic pulse



Interphase delay – the delay (a time value) between cathodic and anodic

phases; this value could be 0 and usually is not longer than the interpulse interval


Interpulse interval – the time between the end of the first pulse and the

beginning of the following pulse
Biphasic waveforms can lead with either the cathodic or anodic phase. In addition, the
pulse widths and amplitudes of each phase can be intentionally mismatched. And finally,
the pulse train has the following important parameters:


Pulse period – the time between the beginning of two successive pulses
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Pulse repetition frequency – this is equal to 1/period and is commonly

referred to as the stimulation frequency
Figure 4 illustrates a pulse train, with parameters annotated, constructed from biphasic,
charge balanced, pulse waveforms with interphase delay.
In certain applications, more complex features are introduced into the stimulus
waveform in the form of amplitude (AM) and/or frequency modulation (FM) of the
parameters. In AM, the amplitude parameters of the individual pulses within the train are
varied; in FM, the time parameters are varied. In auditory stimulation and cochlear
implants, the advantages of AM and FM are well-established100,101. Similar work is being
conducted for DBS102,103.

Figure 4 Example pulse train. The waveform above is a biphasic, charge balanced,
rectangular pulse train. Key parameters are annotated.

1.5

Overview of Dissertation

The contents of this introduction chapter so far have described the current state of
the broad field of electrical stimulation. CHAPTER 1 only serves as a general review of
the established theory and principles. The next three chapters all deal with specific
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applications of electrical stimulation in medical science and practice. Each of these
chapters contains a further review of relevant background information and key findings.
CHAPTER 2 explores the effects of electrical stimulation on alcoholism, a
condition that affects many and has proven to be difficult to treat with conventional
methods. The neural circuitry of reward and addiction has been studied for many decades,
and by stimulating the appropriate parts of that circuit, it is theoretically possible to
modify addiction behavior. Others have attempted to reduce alcohol consumption in
animal studies but have not produced convincing results104,105. Through collaboration
with Dr. Zachary Rodd’s group in Indianapolis, I was able to show that DBS of the
nucleus accumbens shell reduced alcohol drinking in rats. These results have important
implications for treating alcoholism and addiction.
CHAPTER 3 introduces a novel method of designing and studying stimulus
waveforms that has potential to increase the effectiveness of stimulation therapy. This
work originated from the DBS work described in CHAPTER 2. When applied to nerve
stimulation, the vagus nerve in particular, this novel method seems capable of producing
patterns of nerve fiber activation different from the conventional method, which simply
involves delivering rectangular pulse waveforms. The different activation patterns signify
that the efficiency and selectivity of nerve stimulation can be fine-tuned with careful
adjustments of the stimulus based on response feedback.
In CHAPTER 4, the work in CHAPTER 3 is expanded. In addition to
demonstrating how the stimulus can be manipulated to vary the nerve activation pattern, I
show that the differences in the resulting nerve response profiles have a significant
impact on the physiological response as well. Actually, the nerve response has a
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consistent relationship with the ultimate physiological response. As a result, a stimulation
paradigm that allows improved control of the nerve response also provides better control
of the physiological response.
CHAPTER 5 concludes all of the work detailed in this dissertation. This final
chapter reviews the key concepts and summarizes the important results. And finally, there
is a discussion of the significance of the results and ways to expand this work.
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CHAPTER 2. DBS TO TREAT ALCOHOL USE DISORDER

2.1

Introduction to Alcohol Use Disorder

Alcohol use disorder (AUD) – alcohol abuse and dependence – is a highly
prevalent condition with serious health and societal impacts14,106,107. An estimated 30% of
the U.S. population will suffer from AUD during their lifetime106, and in the world, about
125 million people suffer from AUD14. Patients with AUD have 1.8 to 9.5 times higher
mortality rates than the general population, and death from accidents, particularly motor
vehicle collisions, is common108–110. Existing treatments can be effective but only
temporarily so, because about 50% of patients become noncompliant or relapse in just
one month8,9,111–113.
Deep brain stimulation (DBS) offers a promising alternative to conventional AUD
treatments16 and may provide reliable treatment with sustained long-term effectiveness.
Recent clinical studies and reports have shown that DBS can reduce alcohol intake and
craving114–116 as well as other addictive behavior, such as cigarette smoking, drug use,
and overeating117–119. Animal studies suggest the same104,105,120–123. However, there are
still concerns about beginning large-scale clinical trials. The major criticism is that there
is not enough evidence on long-term efficacy and safety in animals to justify such an
invasive and risky intervention124–127.
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There is actually not much animal data on the effects of DBS on alcohol
consumption in general124–127. One study showed that DBS can reduce alcohol intake but
relied on a saccharin fading procedure to induce alcohol drinking105. Another study used
P-rats, which voluntarily drink alcohol, but the study yielded inconclusive results due to
very low levels of alcohol intake104. The P rats are a unique breed of rats with
characteristic alcohol preference and intense alcohol drinking behavior128,129, which make
them a good model for studying alcoholism130,129.
This chapter presents a set of experiments characterizing the effects of DBS on
voluntary ethanol consumption in the P rats. These experiments were aimed to provide
more efficacy data from animal studies. The results of this work contributed to the
increasing amount of evidence that supports the use of electrical stimulation in treating
AUD and related disorders.

2.2

Experimental Design and Methods

These experiments were designed and conducted in collaboration with Dr.
Zachary Rodd’s research group in Indianapolis. The animal experimentation took place in
Indianapolis.

2.2.1

Animals and Surgery

Adult female alcohol-preferring (P) rats weighing 200 to 350 gm from the 78th
generation were used in this experiment. Female rats were used because they maintain
body weight and head size better than male rats for more accurate stereotactic placements.
Rats were double-housed upon arrival to the lab and maintained on a 12-hr reverse light-
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dark cycle (lights off at 9:00 AM). Food and water were freely available throughout the
experiment except in the test cage. Animals used in this study were maintained in
facilities fully accredited by the Association for the Assessment and Accreditation of
Laboratory Animal Care. All research protocols were approved by the institutional
animal care and use committee and are in accordance with the guidelines of the
Institutional Care and Use Committee of the National Institute on Drug Abuse, NIH, and
the Guide for the Care and Use of Laboratory Animals (National Research Council,
1996).
A twisted pair of Platinum electrodes (Plastics One, Inc.) was implanted into the
left nucleus accumbens shell (AcbSh) of each animal. The AcbSh is a major center in the
reward/addiction circuitry131,132. Unilateral implantation was performed instead of
bilateral, mainly to simplify the surgery and experimentation. Left sided implantation was
chosen based on a previous human study, which demonstrated abnormal neural activity in
the left AcbSh only (i.e. no change in right AcbSh) in response to drug-related cues115.
Target coordinates for the AcbSh were 1.6 mm anterior to bregma, 2.4 mm lateral to the
midline, and 8.5 mm ventral from the surface of the skull at a 10-degree angle to the
vertical.
Each electrode terminated in two female sockets that were connected to a multichannel electrode pedestal, which was secured firmly using cranioplasty (OrthoJet)
layered around the device and over three stainless steel screws fastened to the skull. After
surgery, rats were individually housed and allowed to recover for at least 2 days before
resuming testing.
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2.2.2

Experimental Setup

The DBS system consisted of an “animal proof” stainless-steel-shielded cable that
attached the implanted electrode pedestal and to an electrical commutator (all from
Plastics One, Inc.), which allowed free movement within the cage. The commutator was
mounted over the top of the testing cage, which is 30 x 30 x 26 cm (w x h x d) in size. A
waveform generator (Agilent 33522A) was used to design the stimulus waveform, and a
custom-made current pump was used to convert the voltage waveform to a constant
current waveform (more detail on the current pump can be found in Section 3.6). The
stimulus parameters were as follows: biphasic, rectangular pulses with no interphasic
delay, pulse frequency 150 Hz, pulse width 100 μsec, and current intensities of 100 μA
(n=3) or 200 μA (n= 4).
The implanted electrodes were checked periodically by performing
electrochemical impedance spectroscopy with a Gamry Reference 600 Potentiostat
(detailed methods can be found in Section 3.6). The functionality of the DBS system was
tested before each stimulation session by checking the stimulator output via a digital
multimeter (Agilent 34410A) in series with the stimulator and electrodes. All
measurements were done outside the 60-min testing session and did not interfere with
behavior testing.

2.2.3

Experimental Design and Data Analysis

In the testing cage, 15% non-flavored ethanol (EtOH) and water were freely
available, via two separate 15 mL graduated tubes. Rats were placed in the training box
with access to the fluids for one hour a day (limited access) each day for 4 weeks to
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establish consistent alcohol intake behavior. Alcohol-preferring P rats are natural drinkers
and do not typically require food/water restrictions, or sucrose fading procedures to
acquire stable daily alcohol intake in a free choice limited access setting128,129. Once
chronic drinking levels were established and stable over several days, rats underwent
surgery for DBS lead placement. After a recovery period of 2 days, the rats resumed the
daily 1-hour sessions in the training box.
During the first postoperative week, the rats were tethered to the DBS system but
did not receive any active stimulation. This period allowed each rat to acclimate to the
new sensation of the cable and reach a new post-implant baseline of alcohol intake. In the
second postoperative week, once rats re-established alcohol drinking behavior, DBS was
delivered to the rats in the training box for 5 minutes prior to and during the entire 60
minute drinking session.
DBS therapy occurred each day during the 1-hour session for 5 days at 100 μA in
3 rats and for 6 days at 200 μA in 4 rats. A technical issue in the 100-μA group caused
the DBS to not be delivered on Day 1, but this was not identified until after the
completion of the experiment, leaving just five days of active DBS data for analysis. All
7 rats underwent an additional 3 daily post-DBS sessions, during which they were
tethered but not stimulated to assess for any post-treatment effects. At the completion of
the experiment, rats were euthanized by CO2 inhalation. Brains were then removed, and
histology was examined for accurate placement of electrodes to confirm proper
implantation.
The analysis for the DBS data was simplified since there were not enough values
to fulfill the degrees of freedom requirement to perform a mixed factor ANOVA.

24
Therefore, paired t-tests were performed comparing baseline EtOH consumption to intake
during test session. To adjust for multiple comparisons, the p value of significance was
lowered to p < 0.01.

2.3

The Effect of DBS on Alcohol Intake

DBS delivered at 100 μA temporarily reduced EtOH consumption (see Figure 5)
with 35% and 43% decreases on Days 2 and 3 (p values < 0.002) but no effect on Days 1,
4, and 5. DBS delivered at 200 μA consistently reduced EtOH consumption, with a 35%,
42%, 53%, and 59% decrease on Days 3, 4, 5, and 6, respectively (p values < 0.0018;
Figure 6). There was no effect of DBS on water intake, indicating that the stimulation
did not affect overall fluid intake or interfere with normal animal behavior. Baseline
intake levels in both groups would have resulted in blood ethanol concentrations ranging
from 75-125 mg%; these levels are much higher than what others reported104.

Figure 5 Ethanol (EtOH) intake in the 100μA group. The average EtOH intake per
1-hour session is plotted over time. Data were collected each day during DBS delivery
Stim1–Stim5) and for 4 days after the last day of DBS delivery (Post1–Post4).
Baseline is estimated by averaging the intake for 3 days before stimulation. Data were
obtained from a total of 3 rats.
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Figure 6 Ethanol (EtOH) intake in the 200μA group. The average EtOH intake per
1-hour session is plotted over time. Data were collected each day during DBS delivery
(Stim1–Stim6) and for 3 days after the last day of DBS delivery (Post1–Post3).
Baseline is estimated by averaging the intake for 3 days before stimulation. Data were
obtained from a total of 4 rats.
At 100 μA, there seems to be only a transient decrease in alcohol intake in the
subjects. However, at 200 μA, the effect is more sustained. Also, the effect seems to be
reversible, with intake rebounding to baseline levels after the stimulation either is no
longer effective or is turned off.

2.4

Discussion

DBS of the AcbSh seemed to be capable of reducing alcohol drinking in alcohol
preferring P rats. Considering that the overall amount of stimulation is fairly low, only
about 1 hr per day, and that only unilateral stimulation was delivered, the observed
significant effect on alcohol drinking behavior is highly promising. DBS may just
provide the type of lasting treatment that is specific, adjustable, and less dependent on
patient compliance.
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However, as can be seen in the difference between the 100 and 200 μA test
groups, the stimulus parameters can dictate the success of the therapy. The two
amplitudes, 100 and 200 μA, were chosen somewhat arbitrarily when designing the
experiment, with prior studies in mind104,105. Though the final behavioral effect can be
measured, the exact neural response to the stimulation is unknown.
With only physiological or behavioral data as feedback and no neural response
data, it is difficult to determine the stimulus parameters to ensure that the patient or
subject is receiving appropriate stimulation. Too little stimulation can result in lack of
therapy or loss of therapy over time, as seen in the 100 μA group. Too much stimulation
may result in harmful side effects. Dosing for each individual is a major challenge in the
field of electrical stimulation today.

2.5

Developing a Better Method for Stimulus Waveform Design

The next two chapters present a new way to design and assess stimulus
waveforms. The work builds on the thesis of Dr. Matthew Ward133, who provided a
stimulation system to characterize and analyze the neural responses to different stimuli.
This system, termed Autonomous Neural Control (ANC), allows users to empirically
determine how neurons will respond to stimulation. The neural response then can be
matched to the physiological or behavioral response. This way, determining the stimulus
parameters can be objective, involving less guesswork.
So far, ANC is best developed for nerve stimulation, with particular focus on the
vagus nerve due to the many applications of vagus nerve stimulation therapy. When
stimulating the nerve, the response is relatively simple, because the nerve is a neatly
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organized, essentially parallel bundle of axons, whereas the brain is a vast network.
Though the nerve response can be more easily captured and quantified, the vagus nerve is
by no means simple. Stimulating the vagus nerve can cause many different effects, and
these effects can be matched to the nerve response. Therefore, vagus nerve stimulation
provides a good platform for testing methods to optimize stimulus parameters.

2.6

Notes

With permission from Journal of Neurosurgery, some portions of the texts and
several figures in this chapter were reproduced and adapted from the published article
Wilden et. al.134, which is the fruit of the collaboration with Dr. Rodd’s group and
contains my original work.
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CHAPTER 3. BURST-MODULATED STIMULUS WAVEFORMS

3.1

Introduction to Vagus Nerve Stimulation and Its Challenges

Electrical stimulation of the vagus nerve is an FDA-approved treatment for
certain types of epilepsy that are resistant to conventional treatments. Vagus nerve
stimulation (VNS) is also approved for treatment-resistant major depression, and it is
under investigation for treating other disorders15. In epilepsy, up to 24% of patients
cannot adequately control their seizures with medication4,5, and among patients being
treated for depression, as many as 50% experience recurrent major depressive episodes135.
Some of these patients, who do not respond to pharmaceutical therapy, do respond
positively to VNS. Response rate to VNS is about 25-45% in patients with drug-resistant
epilepsy17 and about 30-40% in patients with drug-resistant depression136. Though the
anti-depression effect is highly significant, the contents of this chapter will focus mostly
on VNS in epilepsy, the major reasons being that VNS in epilepsy has been studied in
more detail and that the effects are more quantifiable.
A significant amount of patients benefit from VNS, but there are many patients
who do not respond well. Clinical studies generally conclude that patient response rates
increase with time, and tolerability to the stimulation increases as well137–140. However, a
closer look at the clinical VNS data will show that, patients who initially responded to
therapy will continue to respond, and those who did not respond tend to remain
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unresponsive. Ultimately, the patients who do not respond tend to stop treatment. For
example, in a key clinical trial by DeGiorgio et. al.137, 164 patients completed the study,
and out of those, 68 patients were responders, with “response” defined as 50% reduction
in the number seizures. Of the 98 remaining patients, 22 discontinued therapy, and the
mean seizure reduction in this group is only 7%. A retrospective study by Labar138 found
that patients receiving higher levels of stimulation are actually less responsive, and that
patients with more severe epilepsy tend to be less responsive.
Currently, the method for determining VNS parameters—the method of dosing—
is not an exact process. Patients pay multiple clinical visits and have their care providers
manually adjust the stimulation parameters. The intensity is increased slowly and set to a
point slightly lower than the maximum level that the patient can tolerate. If symptom
relief is not enough, then the physician will attempt to increase the stimulation level
without exceeding the maximal tolerable level141. Adjustment is mostly based on the
patient’s perception and the physician’s intuition (there is a safety limit as well that is
somewhat arbitrary). It is not surprising, then, that patients who do not respond well to
VNS are the ones to receive higher and higher levels of stimulation, and that if a patient
does not respond initially, it will be difficult to improve the effects in that patient.
Increasing the overall response rate and reducing the variability among patients
are major challenges. After reviewing the background of VNS, this chapter will propose a
strategy aiming to improve the effectiveness of VNS. This strategy is based on existing
knowledge in the field as well as data collected through original experiments, and it is
devised with the goal of allowing simple, quick translation into the clinical setting.
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3.2

Mechanism of Electrical Nerve Stimulation

In VNS, electrical charge is applied to the nerve to depolarize the axons within
the vagus nerve, evoking action potentials. Generally, electrical charge is delivered
through a set of cuff electrodes that wrap around the nerve. The charge is supplied by a
stimulus generator, which is powered by a battery. The electrodes, stimulator, and battery
are all implanted inside the body (see Figure 7). When a stimulus is applied across the
electrodes that are placed near the nerve, charges move and distribute in the space
surrounding the electrodes and the nerve. In this type of extracellular stimulation (as
opposed to intracellular stimulation techniques that require accessing the intracellular
space), axons will generate action potentials if their membranes are depolarized
sufficiently by the movement of charges.

Figure 7 The Cyberonics VNS device. Left) An illustration of the VNS implant,
composed of the electrode cuffs, connecting leads, and the stimulus generator housed
with a battery. Right) Close up of the electrode cuffs. Reprinted with permission from
Cyberonics, Inc.
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Though it affects all axons within the nerve, the stimulus has a stronger effect on
the axons nearer to the nerve periphery and closer to the electrodes. However, since there
is not enough evidence to suggest that the axons within the vagus nerve are spatially
distributed in a consistent, predictable manner, VNS is not specific for axons with respect
to the axon’s target and function.
Aside from target and function, there are factors that do influence how individual
axons respond. In the vagus nerve, as in the entire peripheral nervous system, some axons
are myelinated by Schwann cells. The axon together with its myelin sheath, Schwann
cells, and endoneurium are referred to as a nerve fiber; the term fiber pertains to even the
unmyelinated axon with its endoneurium. In the vagus nerve, 70-90% of all nerve fibers
are unmyelinated, and the rest are myelinated to different degrees142,143. The axons with
larger diameters tend to have more myelination144, and the larger, more myelinated fibers
conduct action potentials at faster velocities145–147. Nerve fibers are historically grouped
by their conduction velocities as summarized in Table 1 (compiled from multiple
sources15,142,146,148,149).
With typical electrical stimuli, fast-conducting fibers have lower activation
thresholds24,58,97,150–152—the lowest stimulus intensity that can elicit an action potential.
The smaller, slow-conducting fibers of the nerve are harder to activate50,153,154. Therefore,
though all the axons are affected during stimulation, generally more of the larger, faster
fibers will respond to each stimulus. As such, electrical stimulation is intrinsically
selective for larger fibers, a characteristic that is important for understanding the effects
of VNS.

32
Table 1. Nerve fiber classification and function
A fibers

B fibers

C fibers

Diameter (micron)

5 – 10

2–5

<2

Myelination

Thick

Thin

None

Conduction
velocity (m/s) *

> 10

1.5-20

<6

Direction

Efferent & afferent

Efferent

Afferent

Main function

Somatic motor, fast
pain, epicritic
sensation,
proprioception

Vasomotor,
visceromotor
(autonomic)

Nociceptive and
visceral sensory

Relative activation
threshold

Low

Medium

High

* Large overlap in conduction velocity range is due to discrepancies, which may arise
from differences in recording setups, animal models, and methods of calculation.

3.3

Effects of VNS

The vagus nerve (cranial nerve X) is a large collection of axons that innervates
tissues and organs spanning from the face/head region down to the colon. The axons that
innervate skeletal muscles for swallowing and speech originate from the nucleus
ambiguus in the medulla. The soma in the nucleus ambiguus also send efferents to the
heart, which, together with the efferents to the respiratory and abdominal organs from the
dorsal motor nucleus (also in medulla) of the vagus, constitute the major parasympathetic
pathway of the body. In addition to efferents, the vagus nerve contains many sensory
afferents that synapse in nuclei also found in the medulla. A small portion of the vagus
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nerve relays general sensation to the spinal trigeminal nucleus. More importantly, vagal
afferents are responsible for monitoring the cardiovascular and respiratory systems,
digestive, and other abdominal organs. These pseudounipolar axons synapse in the
nucleus tractus solitarius (NTS)155. Figure 8 illustrates key components of the functional
anatomy of the vagus nerve.

Figure 8 The vagus nerve anatomy and composition. Only the proximal portion,
down to the thoracic region, of the vagus nerve is shown. Nearby nerves are illustrated
as well. The figure is reproduced from an open source review article176.
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Due to the complex nature of the vagus nerve and the nonspecific nature of
electrical stimuli, VNS can create a wide range of effects in the body, some of which are
on the heart and are of particular importance. Stimulating cardiac portions of the vagus
nerve on either the left or the right side will activate the parasympathetic efferents to the
heart, producing negative chronotropic (decreased heart rate), inotropic (decreased
contractile force), and dromotropic (decreased conduction) effects. The left and right
vagus nerves both innervate the heart, but they are not symmetric156. Stimulating the right
vagus has strong negative effects on heart rate and contractile force, and though
stimulating the left vagus has stronger negative effects on the atrioventricular nodal
conduction156–158, this dromotropic effect is less of a clinical concern than the bradycardia
and low cardiac output caused by stimulating the right vagus. Therefore, in patients with
epilepsy, VNS implants are typically only implanted on the left side, so that harmful
cardiac effects are avoided.
Heart-related effects aside, the other effects of VNS can also have clinical impact
on patients; these effects are mostly side effects. Ignoring the surgery- and device-related
complications (such as infection, scarring, etc.), side effects manifest in the nervous
system (pain, paresthesia, headache, dizziness, etc.), respiratory system (dyspnea,
pharyngitis), and in the digestive system (dysphagia, nausea, vomiting). The most
common ones are coughing and hoarseness/voice alterations136,140,141,159,160, which
correspond to the stimulation of the motor efferents to the larynx. Since the motor
efferents, which are the fast conducting fibers, generally are the easiest to activate, it is
not surprising that VNS leads to strong motor-related side effects. Though the side effects
improve over time, the severity of side effects and how well each patient tolerates the
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side effects are important factors when determining the proper stimulus intensity, because
tolerability limits the stimulus intensity.
The observed side effects are consistent with the activation of vagal A and B
fibers, but how VNS leads to the observed therapeutic effects is less clear. Considering
the composition of the vagus nerves, which is dominated by small, slow-conducting
axons142,143—afferent C fibers—many have suggested that the central effects (e.g.
antiepileptic, antidepressant) of VNS are caused by activating the afferent
pathway15,148,161,162. Because VNS can cause activation of the neurons in the NTS and
thus influence many structures in the brain associated with the NTS, this conclusion is the
most intuitive. In a particular study by Zabara162, the stimulus was still effective in
suppressing motor seizures even after the vagus nerve was transected distal to the
stimulating electrodes. However, there is no evidence that directly links therapeutic effect
to C fiber activation. For example, vagotomy alone may have anticonvulsive effects.
Some studies have argued that C fibers are not involved at all in the mechanism of
VNS, and that efferent fibers (most likely B fibers) are more important for therapy (at
least for epilepsy)163–165. In the key study backing this argument, Krahl et. al. used
capsaicin, an excitotoxin more selective for C fibers, to destroy C fibers and eliminate C
fiber activation. They then found that VNS is still effective in seizure suppression164.
However, this study failed to provide electrophysiological data that C fibers were indeed
destroyed. Also, the method used to achieve fiber-selective stimulation is not suitable for
patient use, and so the experiment cannot be translated into the clinical setting.
Overall, neither the Krahl et. al. study nor any other study has produced definitive
evidence to link certain fiber group to the therapy. It may be that the therapeutic effects
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of VNS are due to activation of a combination of nerve fiber groups. To assess how
different fiber activation patterns changes the effects of VNS, it is necessary first to have
methods to alter the fiber selectivity of the stimulus.

3.4

Existing Methods for Selective Stimulation

3.4.1 Selective Conduction Block
It is possible to block conduction in fiber populations without chemicals. In a
2004 article, Bhadra & Kilgore thoroughly summarized the method of blocking with
direct current, which involves holding a nerve segment at a depolarized or hyperpolarized
state with an extra set of blocking electrodes proximal and distal to the stimulating
electrodes166. This technique is more effective at blocking larger fibers, as well as fibers
near the surface. Similarly, the set of blocking electrodes can generate alternating current
waveforms to block conduction167,168, and again, larger fibers are more susceptible. These
electrical block methods, though less damaging to the nerve, still are not much different
from the chemical methods. In addition, the blocking stimuli can be very energy costly,
which is a non-trivial concern for battery-powered implants.
Overall, conduction block is not an appropriate strategy for altering fiber
selectivity VNS treatment, because, as mentioned before, blocking conduction in vagal
fibers and silencing their activity will have large system-wide effects and may interact
with or confound the therapeutic effects of VNS. Conduction block is also not a practical
strategy in the clinical setting for the following reasons:
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- The extra blocking electrodes would require more space and further complicate
surgery
- The blocking waveform would greatly increases the energy consumption
- The impaired conduction would lead to a different set of side effects
Therefore, it is better to control the fiber selectivity of VNS without modifying properties
of the nerve.

3.4.2

Fiber-Selective Electrodes

Different electrode designs can produce different patterns of fiber activation
without conduction block. Using a penetrating microelectrode array, Branner et. al. were
able to access nerve bundles and fascicles169. Using a multi-contact electrode cuff that
flattens the nerve, Tyler & Durand were able to achieve selectivity without penetrating
the nerve170. Though effective, these electrodes are more invasive than the cuff and are
not in use clinically. In addition, with these electrodes, to selectively activate target nerve
bundles and fiber populations requires mapping different portions of the nerve to the
different contact sites. Implementing this system requires a level of data processing and
computation that is difficult to implement in an implantable device.
It is also important to note that these electrodes offer only spatial selectivity. The
multiple contacts can be used independently to activate portions of the nerve, but there is
still no control over which types of fibers are activated. Fiber group selectivity can be
achieved only if the individual contacts are making contact with separate fiber groups.
However, in the vagus nerve, there is no specific spatial organization. The bundles of
fibers going to the different end targets all contain their own mix of fiber groups142,143,149.
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3.4.3

Fiber-Selective Stimulus Waveforms

Achieving different patterns of fiber activation with different stimulus waveform
designs is perhaps the best strategy. Though it may not be the most selective, this strategy
does not create any additional disruption or damage to the nerve and does not raise much
safety or feasibility concerns for future integration into VNS implants. Different stimulus
waveforms can be implemented with standard cuff electrodes and without additional
instrumentation. Finally, without conduction block, the nerve behaves in a more natural
manner.
In the past, stimulus waveforms with various pulse shapes have demonstrated
adjustable fiber selectivity. Quasi-trapezoidal and quasi-triangular pulses that have a
steep rising edge and a slow decay over millisecond scale can be designed to be selective
for small fibers30,171–173. The reverse quasi-trapezoidal or quasi-triangular pulse (a slow
rise with steep falling edge) can also be selective for small fibers, but it is less so than the
normal quasi-trapezoidal pulse, and it requires more charge per phase for nerve
activation173. Other non-rectangular pulse shapes have been investigated as well and have
been shown to be more efficient for neurostimulation96,99, and they may also be selective
for different fiber groups. Table 2 contains an illustration of these pulse shapes.
However, all the non-rectangular pulse waveforms suffer from a common flaw—
they are difficult to implement in an implantable device. Rectangular pulses can be
generated simply by switching the stimulus on and off, but non-rectangular pulses require
the processing unit to create the digital waveform and convert it to an analog stimulus, a
process that is much more energy costly.
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Rectangular pulse waveforms can be cleverly designed to be selective for certain
fibers. Grill & Mortimer have shown that the activation threshold of different fiber
groups can be altered by applying hyperpolarizing or depolarizing prepulses to condition
the axon membrane, before delivering the stimulus pulse97,150. These pulse shapes tend to
be stepwise ramping rectangles (see Table 2 for illustration).
Table 2. Stimulus pulse characteristics compared to the rectangular pulse
Maximal
efficiency for
small fibers*
--

Maximal
selectivity for
small fibers
+++

Notes

Reverse quasitrapezoidal/quasitriangular

---

+

Same as non-reversed

Gaussian

+

Unknown

Hyperpolarizing
prepulse

--

--

Depolarizing
prepulse

-

++

The stimulus itself is more
efficient, but it incurs the
higher pulse generator
energy cost.
Intended for targeting large
fibers. Degree of
selectivity slightly
adjustable at the cost of
efficiency.
Degree of selectivity
slightly adjustable at the
cost of efficiency.

Pulse shape

Quasitrapezoidal/quasitriangular

The stimulus itself requires
more current/charge; the
pulse generator would also
require more energy to
generate these waveforms

* Note that efficiency generally decreases with increasing selectivity for these waveforms.
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Hyperpolarizing prepulses, which causes the inactivation gates of the voltagesensitive sodium channels to open, increase the excitability of nerve fibers. Conversely,
depolarizing prepulses, by closing the inactivation gates, decrease excitability and
increase activation threshold. Because large fibers respond more to electrical
stimuli24,58,97,150–152, which applies to the prepulse as well, the prepulses affect the
activation threshold of large fibers more, and the stimulus can be designed to be more or
less selective for large fibers. Though this type of stimulus waveform is not as effective
as quasi-trapezoidal waveforms in eliminating the larger fiber response173, it is more
easily implemented with a stimulator, and it has the extra ability to increase the
selectivity for large, fast fibers.
Second, because the prepulses are low-intensity stimuli, they only affect fibers
near the surface; deeper fibers have normal activation thresholds97,150. When aiming to
activate large portions of the nerve, a stronger pulse must be delivered to recruit deeper
fibers, and so a stronger prepulse must be also delivered to condition the deeper fibers.
However, increasing the prepulse duration would decrease the change in activation
threshold150, while increasing the amplitude may cause the prepulse to be suprathreshold.
Therefore, the prepulse strategy is only valid for lower nerve activation levels.
Finally, despite using long pulses with low amplitudes, the prepulses are still
capable of activating large, fast fibers. As reported by Vuckovic et. al., a 0.31mA, 0.8ms
depolarizing prepulse did not activate any fibers in the pig vagus nerve, but a 0.4mA,
0.8ms prepulse did activate a portion of the Aβ fibers173, the fastest subgroup of A fibers.
The 4mA, 0.2ms stimulating pulse that followed the suprathreshold 0.4mA, 0.8ms
prepulse then elicited a lower Aβ response about 1ms after the first Aβ response, while the
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nerve response to the subthreshold 0.31mA, 0.8ms prepulse plus the 4mA, 0.2ms
stimulating pulse is about the same as the response with a rectangular pulse. In fact, it
seems that it is because portions of the Aβ fibers were activated by the prepulse and thus
refractory that the stimulating pulse activates fewer fibers. In essence, when prepulses are
applied to condition the fiber groups to a stimulus pulse, the large fibers may fire two sets
of action potentials for every one set of small fiber action potentials. As a result, it is
difficult to maintain the frequency of the stimulation and ensure consistent nerve
response when changing the prepulse parameters.
With electrical stimulation, overall selectivity is low, and even minor shifts in
selectivity may lead to significant effects. Table 2 provides a summary of the
characteristics of the relevant stimulus waveforms. It compares the efficiency of the
waveforms at activating nerve fibers and the fiber selectivity, using the rectangular pulse
as the standard.

3.5

Introducing Burst-Modulated Stimulus Waveforms

Because of the flaws in the existing fiber-selective stimulation strategies, I
developed a different method of designing stimulus waveforms, termed burst modulation.
In contrast to standard rectangular pulse waveforms, which are created by repeating
rectangular pulses with defined pulse width (PW) and amplitude (AMP, could be voltage
or current), burst-modulated waveforms are created by repeating bursts of much narrower
pulses, termed “pulsons”. Pulsons can be rectangular in shape as well, so that they can be
generated in the same simple on-off, switch-like manner. An example of burst-modulated
waveforms is illustrated in Figure 9.
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Figure 9 Rectangular pulse and burst-modulated waveforms. A comparison of the
standard rectangular pulse waveform and a 2-pulson burst waveform, with stimulus
parameters annotated. Both are biphasic, cathode-leading, charge-balanced waveforms
with the same repetition frequency. In this example, IpI2 exists to simplify calculations
and comparisons. simplify calculations and comparisons. Reprinted © 2015 IEEE.
When a pulse is to be delivered, the stimulator generates a burst of pulsons in
place of a single rectangular pulse. In burst modulation, only the pulse shape is replaced;
other stimulus parameters such as stimulation frequency and train duration are not
modified. For a burst of pulsons, each pulson has a defined pulson width (pWx, x
denoting the pulson number in the burst) and amplitude (ampx). The interpulson interval
(IpIx) defines the interval between successive pulsons Number of pulsons (Nop) refers to
the number of pulsons within the burst. There are also two derived parameters that are
useful for characterizing these waveforms: effective PW and burst duty cycle. These
terms and definitions are based on those for the standard rectangular pulse.
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The parameters, i.e. Nop, ampx, pWx, and IpIx, can all be changed independently
in a free-form manner that allows the creation of complex waveforms. To simplify
experimentation and analysis, all pulsons in the burst can be set to be identical (e.g. pW1
= pW2 = pWx). Even with identical pulsons, the stimulus waveform has many more
degrees of freedom that can be manipulated. Please see Qing et. al.174 for more details.

3.6

Methods for Characterizing Burst-Modulated Waveforms

3.6.1

Animals and Surgery

Several experiments were performed to test burst-modulated waveforms against
rectangular pulse waveforms. The experiments involved electrical stimulation of the left
vagus nerve in rats under anesthesia. All procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) and adhered to the guidelines set for in the
NIH Guide for the Care and Use or Laboratory Animals (Eighth Edition).
For each experiment, a female, Long-Evans rat (275-350g) was anesthetized with
isoflurane (induction: 5% in 2L/min O2; maintenance: 0.5- 2%). Butorphanol (1.5mg/kg
per 4 hours of surgery) was injected subcutaneously for analgesia. A midline incision was
then made in the ventral cervical region. By dissecting between the infrahyoid muscles
and the sternocleidomastoid, the left carotid sheath was exposed. The left cervical vagus
nerve is inside the sheath and was isolated from the carotid artery.
Two two-lead cuff electrodes were wrapped around the nerve, with the distal one
for stimulation and the proximal for recording. The stimulating electrode was placed
below the omohyoid muscle (which was kept intact), around C-6 vertebra level; the
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recording electrode was placed above the omohyoid, slightly below the carotid
bifurcation, around C-4 level. The typical electrode separation was 7.0mm (range 6.08.0mm, measuring error ±0.25mm).
Initially, the only rationale for having the stimulation electrode more distal/caudal
and the recording electrode more proximal/rostral is so that the nerve response travelling
to the brain is recorded. Because an action potential generated in the middle of an axon
will conduct both ways, swapping the cuff positions yields the same result. However,
because the vagus nerve may branch in the cervical region, stimulating the distal end will
ensure that all stimulated axons are cuffed by the more proximal recording electrodes.

3.6.2

Custom Electrode Design and Fabrication

The electrodes were made in house with braided Pt10Ir microwires (an alloy with
90% platinum and 10% iridium), 0.006 inch total diameter (supplied by Fort Wayne
Metals), and a silicone material for the cuff (see Figure 10 for more details on the cuff).
The microwires were only exposed inside the cuff, with an estimated contact area of
0.011cm2 for each microwire. For each cuff, the microwires were spaced 1mm apart
(center-to-center). The lead-to-lead impedance values of two of these electrodes were
measured to be 0.95 and 0.98kΩ at 1kHz, and the charge storage capacity values were 4.2
and 3.7mC/cm2.
These capacity values are rather high compared to what others reported32, the
reason being that the geometric area was estimated without accounting for the braiding.
Impedance spectroscopy and cyclic voltammetry measurements were performed in
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phosphate buffered saline with a Gamry Reference 600, as detailed in a study by Ward et.
al.175, except a 50mV/sec step was used instead of 1V/sec for cyclic voltammetry.

Figure 10 Cuff electrode for VNS experiments. The electrode leads are made of
braided platinum-iridium microwires (90% Pt, 10% Ir) with total outer diameter of 0.006
inch. The cuff material is made with a silicone tubing with an inside diameter of
0.635mm (AM Systems 806700). The microwires are sheathed in silicone tubing (inner
diameter, id = 0.304mm, AM Systems 806100). Exposed lead segments are threaded
through the cuff, and then silicone adhesive (Nusil MED2-4420 or MED2-4213) is
applied to seal the joints and insulate exposed lead segments outside the cuff lumen. The
leads are spaced 1mm apart. Generally the cuffs are made such that the lumen opens up
to allow the nerve to enter the lumen. The opening then can be closed by wrapping suture
around the outside wall of the cuff, between the two leads. Reprinted © 2015 IEEE.

3.6.3

Experimental Setup

For each trial of stimulation, a 1-second train of 20 pulses or 20 pulson-bursts was
delivered (VNS is commonly set to be 20Hz in both research and clinical
settings136,141,148,162,176), and the nerve response was recorded. All stimuli were chargebalanced, cathode-leading, alternating monophasic waveforms. The alternating
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monophasic waveform, where the anodic charge-balancing phase was applied at half the
period after the cathodic phase, allows artifact cancellation177.
The stimulus waveforms were first generated using MATLAB. A data acquisition
system (DAQ, National Instruments, USB-635x) converted the digital waveform into an
analog voltage signal. A custom-made Howland current pump (with ±10V power supply)
then converted the voltage signal into a current waveform and passed the stimulus to the
distal cuff. The nerve response at the proximal cuff was amplified and conditioned using
a Grass P511 preamplifier, with 1Hz – 10kHz passband, 1000 – 2000x gain, and a 60Hz
notch filter. Through the same DAQ, the conditioned signal was digitized initially at
50kHz. The sampling rate was lowered to 25kHz in later experiments, with no noticeable
differences in signal quality. This experimental setup (see Figure 11) is modified from
that in Ward et. al.177.

3.6.4

Neural Activation Data Analysis

When the stimulus was above threshold, each pulson-burst with effective PW
shorter than the refractory period elicited only a single compound nerve action potential
(CNAP) (see Figure 12). In our experiments, the averaged CNAP signal typically
consisted of two large, distinct peaks. The faster peak (conduction velocity falling in the
range of 10-27m/s) was designated as the A fiber response, and the second, slower peak
was designated as the C fiber response (range 2.5-3.3m/s, see Table 1 and
references145,148). Conduction velocity was calculated by dividing the electrode separation
distance by the peak latency145,154. The height of each peak was designated as the
response magnitude for the corresponding fiber groups. In some animals, the CNAP
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Figure 11 Instrumentation for VNS experiments. (a) Hardware setup for simultaneous
left vagus nerve stimulation and recording. The stimulation cuff is distal to the head; the
recording cuff is proximal. The more distal lead of the stimulation cuff is always
grounded, while the more proximal lead is the active electrode. The active electrode is
driven both cathodically and anodically during stimulation. The more distal lead of the
recording cuff is always the positive differential input into the Grass amplifier, and the
proximal lead is always the negative input. With this configuration, the stimulus artifacts
for the cathodic and anodic phases are always equal and opposite in magnitude. During a
trial, the computer (PC) software generates a digital waveform that is converted to an
analog voltage waveform via the DAC on the National Instruments DAQ. The voltage
waveform is then converted into a current waveform through the improved Howland
current pump. At the start of the stimulus, the software also triggers the DAQ’s ADC to
sample the conditioned signal from the Grass amplifier. (b) Circuit schematic of the
custom improved Howland current pump. The op amp OPA140 is powered by ±10V.
Stim_V is the voltage waveform input, and Stim_I is the current waveform output, with
R3 (1kΩ in this case) setting the gain. A blocking capacitor is placed at the output to
prevent DC leak. The settling time for the pump is about 3μs when loaded with an
electrode cuff and passing 1mA. Reprinted © 2015 IEEE.
peaks have a larger negative component, in which case the negative peak height is taken
as the response magnitude. Other fiber populations and subpopulations did not produce
prominent and consistent peaks and were excluded from analysis.
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For each waveform, the fiber response magnitudes were measured at varying
stimulus intensities (sample responses in Figure 12). For both A and C fibers, the
relationships between the stimulus intensity and fiber response magnitudes were
characterized using sigmoidal recruitment curves (see Figure 13, similar methods have
been used elsewhere169,178). The function used to model the sigmoidal recruitment curves
is:
V (Q)  Vmin 

Vmax
1  exp[ rate * (Q50  Q)] ,

Equation 5,

where V, the response magnitude in μV, is a function of Q the stimulus charge per phase,
with units in nC; Vmin and Vmax are the asymptotes; Q50 is the charge per phase value at
the inflection; and rate is a constant that describes the steepness of the curve and relates
to the rate of fiber recruitment. Curve fitting was done using MATLAB.
Vmin and Vmax correspond to the minimal and maximal response magnitude,
respectively. Rather than assuming it is 0, Vmin is determined by delivering zeroamplitude stimuli. With no charge injection, the resulting nerve recording captures only
noise and baseline nerve activity, and the root mean squared voltage (Vrms) of this
recording is set to be the Vmin. For stimuli with non-zero amplitudes, CNAP peaks in the
A and C fibers latency ranges that have peak heights lying outside the 95% confidence
interval of the noise/baseline peak heights are considered above threshold. All subthreshold CNAP peaks are set to be Vmin.
Response magnitudes were then normalized by first subtracting Vmin and then
dividing by Vmax, yielding recruitment curves based on activation levels (illustrated in
Figure 13). Fiber activation describes the fraction of maximal response of the fiber
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Figure 12 Example processed nerve responses during stimulation trials. The stimulus
waveform (Nop 2, pWx 20μs, IpIx 80μs) was delivered at varying current amplitudes in
random order. For each trial, a 1-second, 20Hz train was delivered. After the artifact was
eliminated177, the individual CNAP responses for each stimulus (thin traces) were
averaged (thick trace, n=20 stimuli). All traces are shown from time 0 to 6ms. The top
trace corresponds to an amplitude of 0, the bottom 1mA, and the traces in between are
arranged in increments of 0.2mA. Peak latencies and heights (o’s) and widths at half peak
height (x’s) were extracted from the averaged signal. Within each trial, the individual
heights of the fiber peaks did not exhibit any order effect or deviation from a normal
distribution, e.g. the peak height did not decrease with subsequent stimuli. The peaks
labeled for the 0mA trial are due to noise and baseline activity. These peaks are not
actual response peaks from the nerve and are ignored. Reprinted © 2015 IEEE.
population that is elicited by a stimulus, and using fiber activation instead of response
magnitude accounts for variability in Vmax across animals.
There also seemed to be variability in Vmax across waveforms within the same
animal, and the fiber recruitment models suggest that some waveforms were capable of
reaching higher Vmax than that of the continuous pulse (as shown in Figure 13). As a
result, magnitudes were all normalized to the Vmax of the continuous pulse. For example,
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Figure 13 Fiber recruitment curves for selected pulse waveforms. Left plots, the
response magnitudes for A and C fibers were extracted from CNAP responses and
plotted against the stimulus charge per phase value. Each data point represents a single
trial of 20 pulses/pulson-bursts. The data points follow a sigmoidal curve (R2 generally >
0.9). All data shown are from the same nerve, same animal. Vmax is the estimated
maximal response achievable with a certain waveform and can differ with each
waveform. Peak magnitudes from sub-threshold stimuli are assigned the Vrms of the
noise floor. Right plots, response magnitudes are normalized to the Vmax of the
continuous pulse, after subtracting Vrms, for each respective fiber group. Q50 values are
calculated from these normalized activation levels. The legend only shows the anodic
phase of the waveform. All waveforms in the experiment are alternating monophasic.
“Chopped” refers to a simple way to generate burst-modulated waveforms by dividing a
rectangular pulse evenly with a certain burst duty cycle (BDC). Reprinted © 2015 IEEE.
the Q50 of a waveform is the charge required to activate 50% of the maximal response
achievable with the continuous pulse.
The charge per phase values, rather than current amplitudes, is used to
characterize stimulus intensities for recruitment curves. Amplitudes can be used to model
recruitment curves as well, but when using waveforms with different pulse shapes or, in
this case, burst-modulated waveforms, the amplitude is insufficient for describing the
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pattern of charge injection. Moreover, the stimulus charge per phase is more closely tied
to energy consumption and battery life in implants.
Because the fiber recruitment rates can differ, as can be seen in Figure 13, both
the efficiency and selectivity of a waveform are dependent on the fiber activation level.
For example, the waveform with the lowest Q50C is the most efficient at activating C
fibers to 50%, but it may not be the most efficient one at 75%. Fiber recruitment curves
give a more complete representation of the nerve’s response than strength-duration or
charge-duration relationships. Recruitment curves can also describe strength-duration or
charge-duration relationships (Mollet et. al.178demonstrated how fiber recruitment curves
can be used to construct strength-duration curves).
Statistical analyses of nerve response data for comparing the waveforms were
performed using SAS 9.3.

3.7

Differences between Pulse and Pulsons

To find the relationship between each burst modulation parameter and efficiency,
different free-form waveforms at varying intensities were delivered in random order.
Because the results from the chopped pulse experiments suggest that the 2-pulson/20μs
pWx (chopping a 200μs pulse with 2 pulsons at 20% yields 20μs per pulson) combination
behaves most differently from the continuous pulse, the 2-pulson/20μs pWx waveform
was selected as the starting point. Fixing the Nop at 2, the pWx was set at 20, 30, and
then 40μs. Then fixing the pWx at 20μs, the Nop was set at 2, 3, and 4. At each NoppWx combination, the IpIx was set to 0, 10, 20, 40, 100, and 200μs (note, waveforms
with IpIx = 0 are equivalent to continuous pulse waveforms, where essentially, Nop = 1).
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Pulson-bursts longer than 1ms (longer than the refractory period) are excluded from
analysis because multiple action potentials were elicited (example in Figure 14).
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Figure 14 Example CNAP response for IpIx = 1ms. The type of data is the same as
shown in Figure 12. The waveform used was a 2-pulson burst with pWx = 20μs and IpIx
= 1ms. For this particular trial, the stimulus artifacts were not cancelled completely. The
sharp artifact near 0 and 1ms mark where the pulsons were delivered. Immediately
following each artifact is an A fiber response, which is then followed by a second one
smaller in magnitude than the first (due to the relative refractory period). The C fiber
response peaks from the two pulsons overlap with each other. Reprinted © 2015 IEEE.
The Q50A and Q50C for all waveforms and animals are summarized in Figure 15.
To assess how burst modulation parameters affect efficiency, the effects of Nop, pWx,
and IpIx on Q50A and Q50C are tested using multiple linear regression, in the form:
Q50   Nop Nop   Nop pWx   IpIx IpIx   animal Danimal  

Equation 6

,

where Q50 (Q50A or Q50C) is the response variable; Nop, pWx, and IpIx are the predictors,
with their corresponding β’s being the regression coefficients; Danimal is the dummy
variable matrix for the animals, and δanimal is the corresponding coefficients; and ε is the
error term. Regression analysis establishes a quantitative relationship between each burst
modulation parameter and fiber recruitment characteristics, allowing prediction and
interpolation of fiber recruitment based on a continuum of parameter values.
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Figure 15 Q50A, Q50C, and level of A fiber activation at Q50C for all waveforms. Q50
values and A fiber activation levels were calculated from recruitment curves for both A
and C fibers. The Nop, pWx, and IpIx parameters are annotated below the box and
whiskers, the units for pWx and IpIx being μs. Waveforms with IpIx = 0 were treated as
continuous waveforms with PW equal the report Nop multiplied by the pWx. n = 3-6
animals for each waveform (low variability for some waveforms is due to having n = 3
animals). Note, data distribution is not always normal. Reprinted © 2015 IEEE.
The regression results (Table 3 & Table 4) suggest that both Q50A and Q50C
increase with increasing Nop, pWx, and IpIx (the p-values for all three coefficients were
< 0.0001 for Q50A and Q50C; residual diagnostics confirmed the regression assumptions).
That is, the charge per phase required to reach 50% A and C fiber activation increases
with increasing Nop, pWx, and IpIx. Among these three parameters, Nop had the most
effect on Q50, followed by pWx and then IpIx.
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Table 3. SAS output for multiple regression of Q50A and burst modulation
parameters
Variable
DF Parameter Standard t Value
Pr > |t|
Estimate
Error
(p-value)
Intercept

1

-3.11132

1.61212

-1.93

0.0558

Nop

1

4.51615

0.42546

10.61

<.0001

pWx

1

0.12007

0.02056

5.84

<.0001

IpIx

1

0.04587

0.00363

12.65

<.0001

R91dummy*

1

18.71064

0.87672

21.34

<.0001

R93dummy

1

15.79666

0.87055

18.15

<.0001

R94dummy

1

-2.88756

0.74810

-3.86

0.0002

R97dummy

1

1.76400

0.74810

2.36

0.0198

7.60904 0.87055
8.74
<.0001
R101dummy 1
* The dummy denotes the variables of the dummy matrix. P-value for dummy variables
simply signify that activation profiles differ among the animals. Reprinted © 2015 IEEE.

Table 4. SAS output table for multiple regression of Q50C
Variable

DF Parameter Standard t Value
Estimate
Error

Pr > |t|
(p-value)

Intercept

1

0.56723

1.06815

0.53

0.5963

Nop

1

3.42476

0.28190

12.15

<.0001

pWx

1

0.09858

0.01362

7.24

<.0001

IpIx

1

0.02722

0.00240

11.33

<.0001

R91dummy

1

6.68427

0.58089

11.51

<.0001

R93dummy

1

10.12777

0.57680

17.56

<.0001

R94dummy

1

-3.86533

0.49567

-7.80

<.0001

R97dummy

1

0.65962

0.49567

1.33

0.1856

1

8.46077

0.57680

14.67

<.0001

R101dummy
Reprinted © 2015 IEEE.

The estimated A fiber activation at Q50C was used to compare fiber selectivity
among various waveforms and across animals. With the recruitment curves for both A
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and C fibers, it is possible to interpolate A and C fiber activation based on a chosen
stimulus intensity. This intensity could be some arbitrary value, e.g. 20nC, or it could be
more empirically chosen and based on the recruitment curves, such as Q50. When
stimulating the nerve at Q50C, the expected C fiber activation would always be 50% with
minor variability regardless of waveform, but the A fiber response may differ
significantly with waveform. In addition, the Q50C value may differ with waveform due
to differences in efficiency.
Using the recruitment curves derived from the parametric analysis, the level of A
fiber activation at Q50C for all waveforms are calculated (plotted in Figure 15). The
effects of Nop, pWx, and IpIx on the A fiber activation are then tested using, again,
multiple linear regression, by using the same regression model as described in Equation
6, except the Q50 term is replaced with A fiber activation at Q50C.
The regression results (see Table 5) show that, while maintaining 50% C fiber
activation, only changing the IpIx has an effect on the level of A fiber activation. For all
animals, increasing the IpIx is correlated with a decrease in A fiber activation (p < 0.0001
for IpIx; p = 0.2019 for Nop; and p = 0.8176 for pWx; residual diagnostics confirmed the
regression assumptions). Though Nop and pWx do not seem to affect selectivity directly,
there may be significant interaction effects.
As an example, Figure 16 demonstrates the effect of varying only IpIx on the
CNAP response. As IpIx increases, the activation levels for both A and C fibers decrease,
consistent with the efficiency regression results. And interestingly, with each increase in
IpIx, A fiber activation decreases more than C fiber activation, which suggests that the
stimulus is becoming more selective for C fibers.
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Table 5. SAS output table for multiple regression of A fiber activation at Q50C.
Variable

DF

Parameter Standard t Value
Estimate
Error

Pr > |t|
(p-value)

Intercept*

1

0.56486

0.06959

8.12

<.0001

Nop

1

-0.02355

0.01836

-1.28

0.2019

pWx

1

-0.00021

0.00089

-0.23

0.8176

IpIx

1

-0.00072

0.00016

-4.61

<.0001

R91dummy

1

-0.43002

0.03784

-11.36

<.0001

R93dummy

1

-0.29535

0.03758

-7.86

<.0001

R94dummy

1

-0.24608

0.03229

-7.62

<.0001

R97dummy

1

-0.10110

0.03229

-3.13

0.0021

0.10665 0.03758
2.84
0.0053
R101dummy 1
* The A fiber activation at Q50C should be non-zero. Reprinted © 2015 IEEE.
The results from comparing different burst-modulated waveforms and rectangular
pulse waveforms suggest that waveforms with short duration of charge injection (short
PW or short pWx) were more charge efficient, requiring less charge to reach 50% fiber
activation. This observation is consistent with modeled and empirical charge-duration
relationships in literature, which all show increasing threshold charge with increasing PW
in an almost linear manner (Weiss’s formula)33,47,48,50,67.
The results also suggest that waveforms without IpIx were more A-selective. The
fiber recruitment profiles show that intervals added during a pulse, i.e. inter-pulson
intervals, can decrease A fiber activation. This observation is also consistent with the
established notions that 1) short-PW stimuli yield lower thresholds for fibers with larger
diameters24,58,151, and 2) sensory fibers and slow-conducting fibers have longer strengthduration time constants—longer chronaxie50,153,154.
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Figure 16 CNAP responses to burst-modulated waveforms. A and C fiber activation
are compared for various waveforms, annotated in figure. The repetition frequency for all
waveforms was 20Hz, train duration was 1 second (n=20 stimuli per trace), and current
amplitude was 0.24mA. For simplicity, only the averaged trace is plotted. At the same
amplitude, the A and C fiber response magnitudes to a single pulse of 40µs are the
lowest. With 2 pulsons and IpIx = 0 (80µs pulse), the magnitudes are highest. As the IpIx
increases in duration, both A and C fiber responses decrease, and A fiber magnitude
decreases more than the C fiber magnitude. Note: when the A fiber response contains a
notably larger negative deflection, the case for this animal, the negative deflection was
used as the peak magnitude. Reprinted © 2015 IEEE.
Regression analysis aside, the lowest Q50C in the data set shown in Figure 15 was
11.49nC (mean of n=6 animals), which resulted from the single 40μs pulse. This
observation reiterates that short pulses are the most efficient. For this efficient, single
40μs pulse, A fiber activation was 38.7% (mean of n = 6) at Q50C. In contrast, at Q50C,
the lowest A fiber activation level for burst-modulated waveforms was just 12.8% (mean
of n=4 animals), which was from a 3-pulson waveform with pWx of 20μs and a long IpIx
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of 200μs. The lowest A fiber activation when using single rectangular pulse waveforms
was 35.0% (mean of n = 6 animals). So overall, the single rectangular pulse waveforms
are not as selective for C fibers.
However, the 3-pulson waveform, though more selective for C fibers, was not as
efficient, with Q50C = 19.6nC. The most C-selective rectangular pulse waveform was the
80μs pulse waveform, with Q50C = 13.2nC and 35.0% A fiber activation. These results
are all consistent with the regression analysis: a short pulse with no IpIx is efficient, but a
pulson-burst with long IpIx tends to be more selective for C fibers.

3.8

Proposed Mechanism of Action for Burst-Modulated Waveforms

As long as the entire burst duration is shorter in duration than the refractory
period, each pulson-burst can only elicit a single action potential and behaves like a
single continuous pulse. This method of supra-refractory charge delivery creates a charge
buildup at the axon membrane in a manner not unlike temporal summation at the synapse.
With the first pulson, fibers that depolarize beyond the threshold membrane voltage will
fire action potentials, and these fibers will be in the refractory period. When the next
pulson is delivered, the refractory fibers cannot respond, but a portion of fibers that did
not activate during the first pulson will fire. The same will be true for subsequent pulsons.
For the fibers that have not fired, because they were partially depolarized by
previous pulsons, these fibers are in a state of decreased excitability. The partial
depolarization causes the inactivation gates of the voltage-gated sodium channels to close,
so that further depolarization results in activation of fewer fibers. Because A fibers are
more readily depolarized by shorter pulses58,152, the sub-threshold pulsons should affect A
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fiber excitability more, which would explain the lower A activation produced by pulsonbursts. The mechanism is similar to that for the pre-pulse introduced by Grill &
Mortimer97,150. The major difference between pulsons and prepulses is that, unlike
prepulses, pulsons do not need to be subthreshold, so each pulson can contribute to nerve
activation in addition to conditioning the nerve.
The higher charge efficiency is due to the fact that the stimulus charge is
delivered as narrow pulsons (microseconds to tens of microseconds). Because pulsons are
generally much shorter than a rectangular pulse, at the same charge level, the pulsons are
much higher in amplitude. Therefore, consistent with the principle that short PW pulses
are more efficient33,47,48,50,67, each pulson is highly effective at activating nerve fibers.
Though not included in the experiments presented earlier, each pulson in the burst
can have different parameters (e.g. pW1 ≠ pW2), creating complex patterns of charge
injection that may be used to further improve efficiency and selectivity. For example, by
using hyperpolarizing pulsons before depolarizing pulsons, it may even be possible to
increase A fiber selectivity by similar mechanisms proposed by Grill & Mortimer97,150.

3.9

Implementation of Burst-Modulated Waveforms

Burst modulation provides more control over the stimulus waveform by
introducing a different set of parameters. The larger parameter space is useful for finetuning the tissue response, but it also makes parameter selection more difficult. For
rectangular pulse waveforms, there are only two parameters—PW and AMP. In contrast,
for burst-modulated waveforms, there are four—Nop, pWx, IpIx, and ampx. In the
experiments so far, representative parameter sets were chosen, e.g. few versus many Nop,
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long versus short pWx or IpIx. The parameters are then randomly combined to create
various stimulus waveforms. This type of parametric sweep is a rather brute-force
approach, but it does quickly yield recruitment profiles useful for comparing different
waveforms. This parametric sweep process is also subject-specific and can serve as a
calibration procedure.
After the parametric sweep, instead of using regression to find the relationship
between the stimulus and the nerve response for a population of subjects (see Equation
6), analysis can be focused on the individual subject to profile the neural response for the
parameters. The stimulus-response relationship then can be used to predict the individual
subject’s response profile for the entire parameters space. This profile can also be
updated with future stimulation trials and parametric sweeps to improve its prediction
accuracy and to allow it to adapt to changes over time.
In addition to improving efficiency of fiber recruitment, another advantage of
burst-modulated waveforms is that the on-off nature of the waveform is easy to
implement in implantable stimulators. It is more difficult, as well as more processing
intensive, to generate the more complex waveforms, such as trapezoidal, step-functions,
and sinusoidal pulses. For example, by using one additional switch, the processor unit of
the implant would be able to generate pulson-bursts instead of standard rectangular pulses.
In fact, there are existing systems capable of generating burst-modulated waveforms179.

3.10 Conclusion
In the experiments described in this chapter, each animal responded differently to
the same stimulus, and more generally, nerve activation profiles differed among subjects
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(even after normalizing the response magnitudes, high variability is apparent in Figure
15 and the regression results). In the clinic, patients are likely to exhibit different nerve
response as well, even though the implant, the surgery, and the stimulus, in addition to
other factors, are controlled carefully. The variability in the nerve response is a likely
contributor to the variability of the effectiveness in patients.
By adding a set of recording electrodes, the nerve’s response to the stimulus can
be characterized in an objective manner. This objective response monitoring is the
essence of ANC. Combining the response feedback of ANC with the systematic method
of designing and analyzing burst-modulated waveforms, the nerve’s response profile to
different waveforms can be quickly captured. With those response profiles, the stimulus
can be adjusted to create the optimal nerve response profiles.
A VNS system with ANC and burst modulation integrated can be used for
studying the mechanism of VNS, pinpointing the fiber group(s) involved. At the same
time, if the target fiber group(s) is known, the same system will enable optimization of
stimulus selectivity and/or efficiency for each subject, boosting efficacy while reducing
side effects and complications.

3.11 Notes
With permission from IEEE TNSRE, some portions of the texts and several
figures in this chapter were reproduced and adapted from the manuscript Qing et. al.174,
© 2015 IEEE, which contains my original work. The manuscript contains a thorough
study of burst modulation on vagus nerve activation and has been accepted for
publication.
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CHAPTER 4. ACTIVATION CONTROLLED VNS

4.1

Introduction to Activation Control

CHAPTER 3 presented a new method of achieving higher fiber selectivity with
electrical nerve stimulation. The foundation this new method is built on a new paradigm
of neurostimulation that will be referred to as activation control. Currently, neural
stimulation (be it in the brain, spinal cord, or peripheral nerves) is performed in an openloop fashion, where the neural response to stimulation (even when recorded180) is usually
ignored, and the physiological effects of stimulation is correlated directly to the stimulus.
This standard stimulation paradigm will be referred to as stimulus control.
In contrast, activation control involves correlating the physiological effect to the
neural tissue response, not the stimulus. In the brain, the response could take the form of
spike activity or evoked potentials, and in nerves, the response would be CNAP. The
same stimulus does not create the same response in subjects; the same stimulus may not
even create the same response in the same subject at all times. Mapping the stimulus to
the response will eliminate many factors that can lead to variability, such as electrode
properties, discrepancies due to surgery, biological differences, and changes over time.
Activation control, then, produces much stronger, reliable correlations. After all, when a
neuron is stimulated, it is the resulting action potentials travelling toward the synapse that
cause a specific effect, not the exact nature of the stimulus.
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In CHAPTER 2, the brain response data to DBS were lacking, and so setting the
parameters was arbitrary. This stimulus control paradigm is rather hit or miss. That the
200μA group experienced a sustained reduction in alcohol intake involved a bit of luck.
The VNS experiments in CHAPTER 3 were comprised of building quantitative
relationships between the stimulus and the nerve response, and this chapter will
demonstrate how the nerve response affects physiology.
In the case of the vagus nerve, stimulation of the A (mostly motor efferent) and B
(mostly parasympathetic) fibers causes obvious physiological effects (discussed in
Chapter 1). Of all the various function of the vagus nerve, its effects on the heart are
perhaps the best characterized and have the most clinical significance. The experiments
summarized in this chapter involve activation-controlled stimulation of the vagus nerve.
These experiments aim to demonstrate that the cardiac effect of VNS can be better
correlated to the nerve response rather than the stimulus parameters. The results have
important implications for the delivery of VNS in patients with epilepsy as well as
patients with cardiovascular disease.

4.2

Vagus Nerve and Heart Disease

The effects of vagus nerve on the heart have been studied for a long time, dating
as far back as the late 1800s181. And unlike the antiepileptic effects of VNS, the major
autonomic functions of the vagus nerve have been well characterized. As mentioned in
Section 3.3, the parasympathetic efferents of the right vagus nerve mostly decrease heart
rate and contractile force, and those of the left vagus nerve mostly decrease nodal
conduction156–158. The left vagus nerve, when stimulated within safe limits, has less of an
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impact on the heart, which is why VNS implants for epilepsy only stimulate the left
vagus. However, researchers are now attempting to harness the cardiac effects of VNS
and have begun experimenting with using VNS to treat cardiac disease. This time, the
parasympathetic fibers of the right vagus nerve are the target.
Heart failure is a very common condition with high morbidity and mortality. In
the US alone, the incidence is 550,000 patients per year, and the prevalence is 5 million.
A chronic, incurable condition, heart failure requires billions of dollars to treat annually
and results in high numbers of hospitalizations. More than 50,000 patients die each year
from heart failure, and due to an aging population, these figures are expected to increase
over time182.
Once the heart cannot adequately provide sufficient output, commonly due to
myocardial infarction and scar formation, the autonomic tone of the body shifts to
sympathetic overdrive. Sustained sympathetic dominance, which can manifest as
increased resting heart rate, higher blood pressure, etc., increases the workload and
energy demands of the heart, which is in turn damaging to the heart and leads to a
downward spiral of cardiac function loss182.
The standard treatment for heart failure is using pharmaceuticals such as betaadrenergic receptor blockers to block the sympathetic system, in addition to using
inhibitors of the renin-angiotensin-aldosterone system, which help to decrease blood
pressure and prevent deleterious cardiac tissue remodeling182. The standard treatment,
however, has limited effectiveness, and mortality is rising even though treatments are
becoming more advanced182. Since restoring autonomic balance is important, as increased
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sympathetic activity and reduced vagal activity are associated with higher morbidity and
mortality, VNS offers a unique potential solution for achieving that balance183–187.

4.3

Epilepsy, Vagus Nerve, and Heart Disease

Aside from its antiepileptic effects, VNS as of late has shown promise for treating
epilepsy in a way very similar to its investigative use in heart failure. Epilepsy is a
serious condition that, in addition to seizures, manifests with a wide range of systemic
effects. Not as prevalent as heart failure, epilepsy nonetheless afflicts as many as 1% of
the population188, and mortality in patients with epilepsy is 1.3 to 9.3 times higher than
the general population189. Though most patients with epilepsy die of causes not directly
linked to seizures, such as brain tumors, infections, and suicide, sudden unexpected death
in epilepsy (SUDEP) accounts for a significant, increasing (increasing because diagnosis
of SUDEP has improved) amount of deaths due to seizures188,190–192. Moreover, patients
with more severe and/or treatment-resistant epilepsy are more likely to encounter SUDEP,
and SUDEP rates are particularly high in the younger population191–193.
SUDEP is a fatal event, the only effective treatment being resuscitation.
Monitoring for seizures and cardiac arrest are helpful for detecting and perhaps predicting
SUDEP, which can aid resuscitation efforts. The key to reducing SUDEP incidence lies
in prevention. Adequate antiepileptic treatment with proper seizure control will
effectively reduce the likelihood of SUDEP, as SUDEP risk increases with frequency and
severity of seizures191–193. In this manner, VNS helps to reduce SUDEP. Recently, a new
potential pathway for VNS therapy to reduce the risk of SUDEP has emerged.
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Evidence gathered over decades suggests that patients who died of SUDEP tend
to have heart disease. Autopsy of patients who succumbed to SUDEP consistently
revealed enlargement and edema of heart, lungs, and liver194, all signs of congestive heart
failure. In addition, autopsy results showed signs of heart disease, including
atherosclerosis and most importantly, myocardial fibrosis195–197. In addition, for patients
<65 years of age living with epilepsy, the risk of dying from heart disease is significantly
higher than the general population198. Overall, in patients with epilepsy, incidence of
myocardial infarction and sudden death are significantly higher as well, so is mortality
from ischemic heart disease198.
Considering that patients with epilepsy and patients who die from SUDEP tend to
be younger than those in the general population who develop heart disease, the cardiac
findings are all suggestive of repeated cardiac insults linked to epilepsy. During seizures,
patients can experience various cardiorespiratory abnormalities, including tachycardia,
bradycardia, even arrhythmias, signs of ischemia, even asystole and apnea199–203, all of
which can contribute to deterioration of cardiac function.
In fact, patients living with epilepsy do show signs of cardiac dysfunction and
disease. Resting heart rate tend to be higher among patients with epilepsy, and
interestingly, patients who are at higher risk of SUDEP had higher heart rate and more
ECG abnormalities204. Much like patients suffering from heart failure, patients with
epilepsy have autonomic dysfunction; more specifically, they also suffer from
sympathetic dominance and decreased vagal activity201,205,206.
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4.4

VNS for Treating Autonomic Dysfunction

For patients with epilepsy, controlling seizures is top priority, because patients
who respond to treatment and have fewer, less severe seizures tend to have lower
mortality and fewer complications. For treatment-resistant patients, in the past few
decades, VNS has served a relatively effective supplemental therapy. In treating epilepsy,
VNS has been limited to the left vagus nerve to avoid harmful cardiac effects. With the
connection between epilepsy and heart disease becoming ever stronger, particularly in the
case of SUDEP, stimulation of the right vagus nerve is beginning to gather attention207.
Now, right-side VNS is being investigated to directly affect the heart, to protect it
from heart failure and seizures. Clinical studies studying the efficacy of right-side VNS in
treating patients with heart failure have produced promising results183,184,208. There is also
currently a large clinical study being performed to assess the direct link between restoring
autonomic tone with VNS and treating heart failure209. In 2014, Schomer et. al. reported a
clinical study that directly aimed to reduce interictal cardiac instability in patients with
drug-resistant epilepsy by stimulating the right vagus nerve207. Right-side VNS in this
study, in addition to reducing seizure activity, was able to improve vagal tone.
The common rationale behind VNS for heart failure and epilepsy is to restore
autonomic balance by increasing parasympathetic vagal activity. In two of the heart
failure studies183,184, patients undergoing VNS exhibited improvements in physiological
and clinical indicators, such as lower resting heart rate and higher ejection fraction, as
well as in the reported quality of life. In the third, a more recent study208, patients
reported better quality of life, though VNS did not seem to improve heart failure
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progression as compared to control. Two of the heart failure studies184,208 reported that
chronic VNS seemed to have led to improvement of parasympathetic tone.
In all these studies, the method for determining the stimulus parameters was the
same as that used in standard VNS practice. That is, parameter adjustment is based on
patient perception and physician’s intuition. As a result, even though parameters are
adjusted on an individual basis, even if the clinical response is used as a feedback, patient
response is highly variable. In the 2008 Schwartz et. al. study183, of the 8 total patients
undergoing VNS, 4 experienced continuing heart function improvement, but 3 received
temporary improvement followed by deterioration, and 1 showed no improvement and
only deterioration for the 6-month study duration. In the 2011 De Ferrari et. al. study184
and the 2015 Zannad et. al. study208, 59% and 62% of patients showed improvement,
respectively. In the Schomer et. al. study207 as well, the improvement of vagal tone is
highly variable.
Another important consideration in right-side VNS is that the side effects can be
much more serious. The De Ferrari et. al. study184 reported serious events that are likely
linked to the stimulus, including atrial fibrillation, hypotension, and syncope. Other side
effects (such as cough, dysphonia, and pain) and surgery- or device-related complications
(such as infections and lead failure) are similar to left-side VNS. And again, the biggest
impact of side effects is that they limit the stimulus intensity.

4.5

The Benefits of Activation Control

The key theory of activation control is that the physiological effect of
neurostimulation is dependent not on the exact stimulus but rather on the neural response.
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More specifically, the same stimulus can produce different neural responses in different
subjects, and the same stimulus delivered at different times can even produce different
responses in the same subject. Conversely, if different stimuli can elicit the exact same
neural response, the activated axons will lead to the same physiological effect, regardless
of stimulus pulse shape, amplitude, etc. (although, the frequency and the stimulation
duration do matter102,141,210).
In VNS, the activation pattern of the nerve, which manifests as a CNAP,
determines the effect of stimulation. As discussed in Section 3.3, A fiber activation would
lead to mostly motor contractions, and B fiber activation would lead to parasympathetic
effects. Accordingly, activation of both A and B fibers will lead to a combination of
motor contractions and parasympathetic effects. The effects of C fiber activation are less
clear, however.
In the clinical heart failure studies183,184, the experimenters reported that, when
setting the stimulation parameters, a reduction in heart rate linked to the stimulation is
considered therapeutic. However, the stimulus did not cause heart rate reduction in all
patients; it was successful in 3 out of 8 patients183 and only 3 out of 32 patients184. The
two main reasons were 1) causing intolerable side effects and 2) reaching the stimulus
intensity limit, which seemed to have been set arbitrarily at pulse width of 1ms and
current amplitude of 5.5mA (perhaps set by device limits).
It seemed that the investigators did not intentionally aim to activate enough B
fibers to cause a heart rate reduction. And much like the mechanism for epilepsy, the
exact mechanism of VNS for heart protection is yet unknown. Dosing by the stimulus
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intensity is an inexact method that introduces high variability, and this way, it is difficult
to determine which fiber group(s) is responsible for the therapeutic effects.
By using the level of neural activation instead of stimulus parameters as the
method of dosing, the physiological response can be controlled more accurately and more
precisely. The benefits of this activation-controlled over the standard stimulus-controlled
stimulation are that:
1.

the activation level is known, allowing accurate assessment of the strength

of the stimulus and lowering the likelihood of under- or over-stimulation;
2.

the nerve response can be matched to the therapeutic and side effects, to

determine exact relationships;
3.

the stimulation produces more consistent responses, resulting in lower

variability and higher response rate; and
4.

different waveforms can be used to elicit different activation patterns for

targeted activation, so as to boost efficacy while reducing side effects.

4.6

Methods for Testing Activation Control

To demonstrate the benefits of activation control, similar VNS experiments as
those described in Section 3.6 were conducted. The experimental setup was essentially
the same as that shown in Figure 11, except a few differences. First, there was an
additional goal of altering cardiac function, so the right vagus nerve was the target. The
expected effect of right-side VNS was to decrease the heart rate, and so the decrease in
heart rate served as the physiological response. To measure the heart rate, a two-lead
surface ECG recording was added, in parallel to the vagus nerve recording. In fact, the
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left-side VNS experiments all included an ECG recording as well, but there were no
notable effects due to the stimulation, so the recordings were not analyzed in detail. See
Figure 17 for a photograph that shows the electrode cuffs wrapped around the vagus
nerve and ECG electrodes attached. Settings for signal conditioning and acquisition were
the same as described in Subsection 3.6.3.
The stimulus frequency remained at 20Hz, and the stimuli were still chargebalanced, cathode-leading, alternating monophasic waveforms. Unlike before, train
duration was 10 seconds, because others have found that the heart rate requires several
seconds to stabilize during VNS211,212. Other train durations (e.g. 5 seconds, 20 seconds)
were tested as well, and 10 seconds seemed to be a good balance between capturing the
full effect and maximizing throughput. Some lower stimulus frequency (e.g. 10Hz, 5Hz)

Figure 17 Animal with nerve cuffs and ECG electrodes attached. Animal is under
isoflurane. The electrode cuffs are wrapped around the isolated vagus nerve. The distal
cuff is for stimulation, and the proximal is for recording. The ECG leads are arranged in
lead II configuration, with the positive lead being near the apex of the heart. The cuffs are
an earlier version of the one shown in Figure 10. The insulation material for these cuffs
happens to be PTFE (black), not silicone. The photograph shows the left vagus cuffed.
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trials were performed as well, and the only difference was that the heart rate change was
smaller and took longer to manifest, simply because fewer stimuli were delivered in the
same amount of time. Therefore, most of the data were collected at 20Hz. Again,
different waveforms and current amplitudes were applied in random order.

4.7

ECG Data Analysis

The nerve signal and CNAP were processed in the same way as described in
Section 3.6.4. The heart rate, unlike for the left-side VNS experiments, was more
important, and so the ECG signal was more carefully processed to ensure that the heart
rate is extracted properly. The ANC system133 contains algorithm for heart rate extraction,
and methods detailed in this section are modified from that existing code. Figure 18
illustrates key steps in heart rate extraction. ECG and nerve data processing was
performed using MATLAB.
First, stimulus artifacts were removed using a smooth function. Setting the
number of points to smooth to 500 generally was sufficient to remove most of the artifact.
This method of artifact removal is simple and fast, but it does distort the waveform and is
only appropriate for determining the heart rate. Next, the smoothed ECG was normalized
by the maximum voltage value, and the R peaks were extracted in the same manner as in
ANC133. The intervals between successive R peaks were calculated and converted to
instantaneous heart rate in beats per minute (bpm). During data analysis, the R peaks
were overlaid on the processed ECG signal and checked manually to ensure proper R
peak identification. See Figure 18 for the results from each step of the processing.
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Figure 18 ECG data analysis. The 10-second raw ECG signal contains large stimulus
artifacts. The artifacts are easily removed by smoothing, though the ECG waveform is
deformed as well. The smoothing does not affect detection of R peaks, which remains the
prominent feature in the recording (denoted by red x’s above each peak). Each ECG trace
and the identified R peaks are visualized and checked for accuracy. The instantaneous
heart rate can be calculated from the intervals between the R peaks. In this example, there
is a notable effect due to stimulation.

4.8

The Effects of Stimulus Parameters on the Vagal Response and Heart Rate

In Figure 19 are two example series of CNAP signals resulting from one stimulus
waveform at different current amplitudes. These CNAP series plots show that,
1.

there are three distinguishable fiber populations with peaks occurring at

different latencies;
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2.

even though the compound action potential complexes do interfere with

each other, which again is a limitation due to the short electrode separation, peak
feature extraction is still representative of fiber activation; and
3.

each nerve has a distinct CNAP signal, even though the same electrodes

and setup were used.

Figure 19 Example nerve responses at varying current amplitudes. The left plot
contains CNAP recorded from animal R164, and the right is from R165. The overall
CNAP morphology for the two subjects is different, even though the setup is the same.
Each plot consists of CNAP data resulting from only a single stimulus waveform
delivered at five different amplitudes (in random order). The red trace is from a zeroamplitude trial, and the trace color shifts toward violet across the spectrum as the
stimulus amplitude is raised. Peak designations are marked with A, B, and C.
To compare the right vagal CNAP response profiles for the different stimulus
waveforms tested, fiber recruitment profiles were constructed in a similar fashion as
described in Subsection 3.6.4. A sample set of profiles is shown in Figure 20. The trends
seen in these profiles are consistent with the results from characterizing burst-modulated
waveforms (see Section 3.7, also refer to Qing et. al.174). Namely, when two pulsons are
delivered back-to-back as a single continuous pulse, the waveform is the most efficient at
fiber recruitment, requiring the least amount of charge to reach a certain level of
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Figure 20 Fiber recruitment profiles for selected waveforms. The response peak
magnitudes for A, B, and C fibers at all charge levels were converted to activation levels
(see Subsection 3.6.4). The burst-modulated waveform with 100μs IpIx recruits fibers
differently from the other two waveforms shown. The other two waveforms are similar in
shape, and their recruitment profiles are similar as well. The black dashed line marks the
50% B activation level, and the gray dashed arrows point to the estimated A and C fiber
activation at 50% B activation.
activation for all fibers. When an interval is added, the efficiency decreases overall, and
the change differs among the different fiber groups, leading to a change in selectivity.
The longer the interval is, the more the waveform deviates from the rectangular pulse.
Although the effects of the different waveforms on the nerve are interesting, the
more important questions are how do the waveforms affect the heart rate and how does
the heart rate relate to the fiber activation. In the sample Figure 21, the CNAP at varying
amplitudes are shown with their corresponding instantaneous heart rate plots. With the
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Figure 21 CNAP and corresponding heart rate. The CNAP plots show only the mean
signal. The same stimulus waveform is used for all four trials shown, and the amplitude
increases from top (zero-amplitude) to bottom (near maximal activation). Arrows mark B
fiber peaks. The average heart rate for the final 5 seconds of the trial is annotated.
zero-amplitude trial, there was no fiber activation, and the heart rate was steady, with
minor fluctuations that correspond to breathing. As the amplitude increased, fibers began
to fire action potentials. However, the heart rate was not affected until B fibers were
recruited, regardless of how large the A and C fiber peaks were. This observation is
consistent with clinical cases where patients were implanted with vagal stimulators on the
right side. These patients experienced seizure reduction without any notable cardiac
effects213, which suggest that other fibers were activated and B fibers were not.
To estimate the heart rate at the end of the trial, the last 5 seconds of the
instantaneous heart rate data were averaged. Under isoflurane, the animal breathed once
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every 1 to 2 seconds, and a duration of 5 seconds, which is longer than at least 2 cycles of
breathing, was deemed long enough to provide an accurate estimate of heart rate.
Occasionally, when the stimulus was strong enough, the heart rate became very
slow and irregular (see Figure 22). Not only is the induced arrhythmia and severe
bradycardia harmful to the subject, which could affect the trials that follow, the irregular
rhythm also makes analysis difficult. In these cases of arrhythmia, it seems that there is
some form of conduction block, which manifests as regular P waves with some missing
QRS and T waves (see Figure 22). Therefore, the stimulus amplitude was generally
limited as to prevent arrhythmia and severe bradycardia. The rats generally have a resting
heart rate of 400 bpm, which decreases and stabilizes around -350bpm under anesthesia.
VNS trials that resulted in a heart rate lower than 200bpm or in overt arrhythmia were
excluded from analysis.

4.9

The Vagal-Heart Rate Relationship

To study the relationship between the vagal response and heart rate, the heart rate
is plotted against the magnitudes of the different fiber peaks in Figure 23. Data from all
tested waveforms (rectangular and burst-modulated) were pooled to create each plot for
each animal subject. Across all subjects, the heart rate seems to be consistently correlated
to B fiber response, decreasing as the B fiber peak increases in magnitude. This
correlation confirms the scientific basis of stimulating the right vagus nerve, because the
right vagal B fibers are precisely the parasympathetic fibers that cause depression of
cardiac function, among other effects (discussed in Sections 3.3 and 4.4).
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Figure 22 Example trial resulting in arrhythmia. The ECG trace is marked with x’s
for R peaks. Initial ECG is normal. The arrows point to several P waves without a QRS
complex, a sign of failed conduction. As a result, the heart rate (estimated from R peaks)
is very low. The average over the final 5 seconds (115bpm) is annotated.
In some subjects, the A and C fiber response appear to be correlated to heart rate
as well. This apparent correlation is mostly due to the fact that the response magnitudes
of individual fiber groups are not independent. A high-amplitude electrical stimulus of
any waveform will activate more fibers in general, so that a when the B fiber response
magnitude is high, C fiber magnitude is likely high as well. Another indication that A and
C fiber activation are not directly related to heart rate is that, for B fibers, the heart rate
decreases as soon as the peak began to appear, while for A and C fibers the heart rate is
steady throughout most of the range of activation. Finally, the heart rate does not change
consistently with A and C fibers across all animals, making a causal relationship unlikely.
A total of 6 animals underwent the right-side VNS experiments, starting with
animals R153 and R154 and finishing with animals R162 through R165. Animals R155
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Figure 23 Right vagal CNAP and heart rate data from all animals. The columns
represent the different fiber groups A, B, and C. The rows represent the different animals
that underwent the experiment. * The data from R162 is more variable because the
anesthesia method used was intraperitoneal ketamine/xylazine injections, whereas the
others were anesthetized with isoflurane.
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through R161 were used for another, unrelated project. So, for the purpose of this series
of VNS experiments, these 6 animals were sequential subjects. This fact is important in
showing that the results are highly reproducible, despite the variability among the
subjects’ CNAP responses and B fiber-heart rate relationships.
As can be seen in Figure 23, the range of B fiber response magnitudes and the
range of heart rate vary among animals. Normalizing the fiber response and heart rate can
reduce the subject-to-subject variability—normalizing the fiber response to the maximal
response magnitude to produce activation levels is the same method used in the burstmodulated waveform study (see Section 3.6.4). However, because high-intensity stimuli
tend to cause arrhythmia and profound bradycardia and were avoided, the maximum peak
magnitudes were unknown. As a substitute for the true maximum, the highest magnitude
for each fiber peak achieved during the randomized stimulation trials served as the
maximum. For normalizing the heart rate, all data were simply normalized to the highest
heart rate recorded. The normalized data are combined in Figure 24.
Normalizing the variables still does not result in a reliable profile for fiber
activation and heart rate across all subjects. Aside from not having the true maximal fiber
response magnitudes, there is also the challenge of accounting for variability among the
fiber response-heart rate profiles for each subject. In the data shown in Figure 23, some
of the B fiber response-heart rate trends appear linear while others are curvilinear.
Therefore, even though it is technically possible to combine the normalized data and
analyze all the data together, it is difficult to create a general profile that accurately
represents all subjects. An individualized approach would be more appropriate.
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Figure 24 Combined normalized data from all animals. The heart rate and fiber
response data are normalized to the highest values encountered. Data from all 6 animals
and all tested waveforms are pooled.
Figure 25 shows the heart rate against B fiber magnitude for two sample subjects
with the individual waveforms marked. It can be seen that as the B fiber magnitude
increases, the heart rate decreases, and though different waveforms were used, the data
points do not deviate from the overall trend. In more general terms, the physiological
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effect is a result of neural activation and not the exact stimulus. The fact that the effect on
heart rate is independent of stimulus waveform highlights the benefits of activation
control. As long as the target fiber group is activated to the desired therapeutic levels, the
stimulus waveforms can be altered to tune the efficiency and selectivity.

Figure 25 Example B fiber-heart rate relationships with waveforms marked. The
heart rate and fiber response data are normalized to the highest values encountered. Data
from all 6 animals and all tested waveforms are pooled. The figure legend for the
waveforms is written as: <Nop>xp<pWx in ms>_p<IpIx in ms>. For example,
“2xp02_p02” refer 2 pulsons with each having a width of 0.02ms and interval of 0.02ms.
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4.10 The Effects of Right-Side VNS on Heart Function
Heart rate alone can be a strong indicator of cardiac workload and can provide a
general sense of the autonomic balance. Using ultrasound imaging, which is a relatively
simple procedure commonly done in the clinical setting, it is possible to determine more
important measures of cardiac function. Combining the electrographical recordings of the
vagus nerve and the heart and the ultrasound images can paint a complete picture of the
effect of each stimulus on the heart.
As a pilot experiment, one animal (R166) underwent right-side VNS with
simultaneous recordings of the vagus nerve and ECG (similar to that described in Figure
17) as well as ultrasound imaging. Ultrasound equipment (Vevo2100, VisualSonics) and
expertise were provided by Dr. Craig Goergen’s group. Image acquisition focused on the
left ventricle of the heart, and image analysis yielded estimates of stroke volume, ejection
fraction, and fractional shortening. Using the heart rate and stroke volume, the cardiac
output can be calculated as well. See Figure 26 for an illustration of image analysis.

Figure 26 Example ultrasound image processing. The left image shows the left
ventricle in diastole with estimated chamber volume marked red; the right image shows
the ventricle in systole with chamber volume marked green. Images show sagittal axis.
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The relationship between vagal CNAP peak magnitudes and the heart rate for this
animal is summarized in Figure 27. Consistent with the results in Subsection 4.8, the B
fiber response is strongly linked to the heart rate. The heart rate is not correlated with A
and C fibers. The baseline heart rate is also similar to those in Figure 23.

Figure 27 R166 vagal CNAP magnitudes and heart rate. The data presented here is
similar to those in Figure 23. Only one stimulus waveform—100μs rectangular pulse
waveform—was used to simplify experimentation.
The stroke volume, ejection fraction, and cardiac output data are shown in Figure
28. The stroke volume is not affected much by stimulation, but ejection fraction does
decrease as B fiber magnitude increases. Though the stroke volume is unaffected, cardiac
output decreases notably due to the lower heart rate. The baseline ejection fraction of 70%
is within the normal range for rats214,215. A decrease in ejection fraction suggests a
decrease in ventricular contractility due to stimulation, which is also consistent with what
others have reported216,217.
With the heart rate data alone, one can only assume that the decreased heart rate
reflects a decreased cardiac output as well. With the additional ultrasound imaging data,
that assumption can be confirmed. More importantly, the availability and feasibility of
performing ultrasound imaging in the clinical setting signifies that the procedure used in
these experiments can be translated to patient care. When setting stimulus parameters,
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vagal recording, ECG, and ultrasound can all be performed, to fully capture the effects of
each stimulus. Then the appropriate stimulus parameters to generate the optimal neural
activation pattern can be determined.

Figure 28 R166 B fiber-left ventricle function relationship. Left ventricle data was
made available by Dr. Goergen’s group. The red asterisk marks an outlier trial, where a
fairly low B fiber activation led to bradycardia and arrhythmia. The data point is included
for completeness.
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4.11 Notes
The contents of this chapter are being prepared for submission for publication.
Likely, the VNS experiment with ultrasound imaging will be repeated a few more times
to collect additional data. The tentative title is “Controlling the vagal effects on the heart
by B fiber activation”. I will be the first author on this article.
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CHAPTER 5. CONCLUSION

5.1

Objective, Individualized Stimulation Dosing

The differences in the B fiber-heart rate profile among the subjects serve as a
strong argument for the implementation of a more objective and individualized approach
to VNS, and neurostimulation in general. The objective aspect can be achieved by 1)
recording the nerve response to the stimulus; 2) creating a profile for the nerve response
to the stimulus; and 3) finding the ultimate effect of the nerve activation on physiology. If
VNS is used for seizure suppression, the physiological effect would be changes in seizure
frequency and severity. For heart protection, in epilepsy or heart failure, the physiological
effect would be resting heart rate and heart rate dynamics, among other indicators. In
spinal cord stimulation, compound action potential analysis is still a valid method for
measuring the neural response. In brain stimulation, the response would be in the form of
evoked potentials or spike activity. This objective approach forms the foundation of
activation control, which allows stimulation dosing based on the subject’s response, and
can reduce subject-to-subject variability.
The stimulus parameters are still important, but they simply are not the major
factor in determining how the body responds. For example, if the stimulator can only
provide a certain amount of voltage, or if the electrodes can only safely pass a certain
amount of current, it is necessary to limit the stimulus amplitude. Also, the efficiency of
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stimulation (charge per phase to achieve target activation) needs to monitored as well,
because the most selective waveform is usually not the most efficient. Draining the
batteries too quickly will require more replacement procedures and increases the risk of
complications. However, just for the purpose of creating a physiological effect, the neural
response is more important than the stimulus. This fact is true at least in the case of
stimulating the right vagus nerve to lower the heart rate. And in this case, the stimulus is
just a means to an end—two different stimuli that can elicit a similar vagal response will
lead to a similar drop in heart rate.
The individualized aspect can be achieved by creating response profiles for each
individual rather than trying to group subjects together for analysis. The group approach
will yield a certain group response rate, because the same neural activation likely does
not produce the same change for everyone in the group. Again using the right-side VNS
as an example, the same level of B fiber activation in different subjects does not produce
the same amount of heart rate decrease (see Figure 24). Dosing each individual subject
based on the unique profile of the subject ensures that each will achieve the optimal
balance of therapeutic effects and side effects.
Implanting more sensors to record more physiological data is not always feasible,
nor desirable. Without constant physiological data feedback, it would not be possible to
perform activation-controlled stimulation. However, during patients’ clinic visits it would
still be better to dose by the patient’s individual neural response rather than just the
stimulus parameters.
The objective, individualized method of neurostimulation used in conjunction
with the described method for optimization for efficiency and selectivity of stimulus
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waveforms, discussed in detail in CHAPTER 1, creates a unique stimulus dosing system.
This dosing system first allows researchers to determine which fiber group(s) is important
for therapy and which fiber group(s) leads to side effects. It also allows clinicians to
determine how to activate the target group(s) in order to maximize efficacy and minimize
side effects. Ultimately, patients should respond in a more consistent manner, and the
overall response rate should increase.

5.2

Refining DBS Parameters

Like for VNS, DBS parameters are also set to produce the maximal clinical effect
without causing intolerable side effects16,89,218,219. Unlike for VNS, due to its more
invasive nature, DBS causes side effects that can be quite severe. Stimulation can
adversely affect 1) cognition, such as causing memory and attention deficits, 2) mental
health, such as inducing anxiety and depression, 3) speech, and 4) functions of certain
cranial nerves218,220,221. In the study by Koller et. al., out of 25 patients, as high as 21
reported paresthesia, and 15 reported headeaches218.
Also unlike VNS, the therapeutic and side effects of DBS are more due to lack of
spatial-, rather than fiber-, selectivity. In other words, enough volume of the target tissue
must be activated to produce therapeutic effect, but activating too much volume will
affect neighboring regions and cause side effects. For example, to reduce parkinsonian
symptoms, the subthalamic nucleus is a common target. By modeling the electric field
from DBS electrodes, Cameron McIntyre et. al. demonstrated the relationship between
distance from electrode and threshold voltage for activation (recall that DBS operates
under voltage-control)60. The results show that stimulation of the subthalamic nucleus
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also activates nearby fibers in the internal capsule, leading to the commonly observed
side effects60,222.
Therefore, increasing spatial-selectivity would increase efficacy and decrease side
effects. Reducing electrode size can improve spatial-selectivity, but a smaller electrode
will have a smaller potential volume of activation. The best way to achieve better spatialselectivity is to improve the accuracy of electrode placement, which is dependent on
surgical and electrode advances.
Nonetheless, activation control and stimulus optimization can still be applied to
DBS. Recording evoked potentials in the region being stimulated and other associated
regions in the brain can yield valuable data on the effects of the stimulus. Simultaneous
stimulation and recording using a standard commercial DBS electrode has been
demonstrated already223. Other methods of recording are also available94,224,225.
Specifically, in stimulating the nucleus accumbens shell for treating alcohol use
and other addiction disorders, the accumbens itself and the prefrontal cortex are major
targets for recording the effect of nucleus accumbens stimulation132,224,226–228. Central and
peripheral side effects can also be monitored. The desired level of neural response, once
determined, can be monitored and maintained, while the stimulus waveform can be
adjusted to fine-tune efficiency and selectivity. Similar systems can be applied to other
applications of DBS as well, such as for treating Parkinson’s disease. Once again, even if
this neural response feedback-driven process can only be implemented during patient
visits, the objective, individualized dosing system still has advantages over the current
standard dosing system.
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5.3

Ideas for Future VNS Work

So far, the VNS experiments aimed to improve stimulus design and dosing system
have shown that the fiber selectivity, as well as efficiency, of the stimulus can be adjusted.
The only major modification required is a set of recording electrodes. Ideally, skin
surface electrodes would suffice, allowing clinicians to record the vagal response without
adding more implantable components. The feasibility and reliability of recording human
vagal responses from surface electrodes will need to be tested.
To fully utilize the benefits of action-controlled stimulation, the stimulator would
need to be able to generate different waveforms. Burst-modulated waveforms can be
rectangular in shape and were specifically designed to allow easy implementation using
microcontroller-based stimulus generators. Incorporation into commercial implants
should be simple but still require testing. A provisional patent229 (the order of inventors
was mistakenly submitted; Kurt Y Qing should be the first inventor) has been filed based
on my work with burst-modulated waveforms, and there is a full U.S. patent in progress
of being filed.
The experiments in CHAPTER 4 characterized the effect of right vagal B fibers
on heart rate. The next step is to characterize the physiological effect of the other major
fiber groups. A fibers should lead to activation of laryngeal muscles. In the rat
experiments or in future clinical studies, laryngeal electromyography would provide
physiological data due to A fiber activation, on either the left or right side. In the rat, it
may be difficult due to limited space. C fiber activation are more difficult to study, since
their effect tend to be slow, prolonged. However, since the subdiaphragmatic vagus nerve
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is mostly composed of C fibers142,143,149, characterizing changes in gut motility may offer
an objective method to measure the physiological effects of C fiber activation.
Finally, the biggest question to answer is whether the different vagus nerve
activation patterns can produce differences in antiepileptic effects (or heart failure, or
other applications). I have conducted some preliminary VNS experiments attempting to
compare the effect of different nerve activation patterns on seizure frequency and severity.
The tetanus toxin rat model of epilepsy230,231 was used. Rats treated with an intrahippocampal injection of tetanus toxin develop frequent spontaneous seizures, which is
similar to the epilepsy syndrome in human patients.
In my experiments, animals treated with tetanus all experienced seizures, one
even died shortly after a seizure. Seizures were detected via a differential recording
across two cranial bone screws and confirmed via video recording (the electrographic and
video recording system used was the Pinnacle 8200). Seizure behavior matched that
described in literature230,231. However, the VNS produced inconsistent results, and so it
was difficult to determine how VNS affected seizures.
The tetanus-treated rats were implanted with two vagal cuffs (same as shown in
Figure 10). Immediately after implantation, it is possible to stimulate the nerve and
record a convincing CNAP response. The impedance across the two leads of the cuffs
increase over time, as measured by electrochemical impedance spectroscopy (same
methods used as described in Subsection 3.6.2). The increase is expected due to natural
tissue scarring, and the electrodes stay viable even months after implant. The longest
implant period is 68 days, and in this animal, the recording cuff impedance at 1kHz
increased from 1.2 before implantation to a maximum of 6.4kΩ in vivo, and the
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stimulation cuff increased from 1.7 to a maximum of 13.7kΩ. However, the vagal signal
deteriorates over time, and a few days after surgery, it is no longer possible to elicit a
CNAP response.
The problem likely lies in the physical properties of the nerve cuffs. Unlike the
commercial ones, which are self-sizing, the custom cuffs are rather stiff and do not selfsize. It could be that over the course of days, due to continued movements of the animal
and scar tissue formation, the electrode leads lost close contact with the nerve. It is even
possible that tissue swelling and scarring from healing, along with irritation from the cuff
due to movement, led to nerve degeneration. A more sophisticated, sizing cuff electrode
is required to preserve vagus function and excitability. Only then can chronic VNS
experiments be conducted properly.
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(http://nciia.org/sites/default/files/newsletter_spring_2009.pdf)
Margaret and Muir Frey Memorial Prize 2nd place, Northwestern
(http://www.northwestern.edu/bme/pdf/BMEnews9-19-08.pdf)

2008 – 2009

2008

113
BMEidea national competition 2nd place, NCIIA
(http://www.nciia.org/RESOURCES/application/pdf/fall2008.pdf)

2008

RESEARCH EXPERIENCE
Biomedical Engineering, Purdue University
Advisor: Pedro Irazoqui
Graduate research assistant
August 2011 – May 2015
- Fabrication and characterization of nerve and brain microelectrodes
- Design, fabrication, and characterization of printed circuit boards for
stimulation and recording in animals
- Design and testing of application-specific integrated circuits
- Developing and conducting animal surgery and experimentation
- Developing and studying rat model of chronic epilepsy
- Biomedical instrumentation
- Custom graphical user interphase and complex routines in MATLAB
- Closed-loop neurostimulation, deep brain stimulation, vagus nerve stimulation
- Statistical analysis
KMC ApneAlert, Northwestern University
Advisor: Matthew Glucksberg
Design team leader
January 2008 – August 2009
- Led circuitry design and modification.
- Led device prototyping and bench top testing.
- Obtained IRB approval and led device testing on human subjects at Prentice
Women’s Hospital in Chicago and Karl Bremer Hospital in Western Cape,
South Africa.
- Wrote grants and secured funding for the project.
- Coordinated research and design efforts with nurses, doctors, and a device
manufacturer in South Africa.
Biomedical Engineering, Northwestern University
Advisor: Robert Linsenmeier
Independent student researcher
September 2007 – August 2009
- Designed and experimented with a real-time recording system for measuring
the pH of cultured human tissue for Children's Memorial Research Center
Biomedical Engineering, Northwestern University
Advisor: Robert Linsenmeier
Undergraduate research assistant
June 2007 – August 2007
- Supported real-time, in vivo oxygen measurements in rat retina by fabricating
recording electrodes and assisting surgical preparations.
- Developed algorithm for data analysis.

PUBLICATIONS
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PUBLICATIONS

Journal Articles
Qing, K. Y., Ward, M. P. & Irazoqui, P. P. Controlling the vagal effects on the heart by
B fiber activation (tentative title). (In Preparation). (2015).
Qing, K. Y., Ward, M. P. & Irazoqui, P. P. Burst-modulated waveforms optimize
electrical stimuli for charge efficiency and fibre selectivity. IEEE Trans. Neural
Syst. Rehabil. Eng. (Accepted). (2015).
Wilden, J. A., Qing, K. Y., et. al. Reduced ethanol consumption by alcohol-preferring (P)
rats following pharmacological silencing and deep brain stimulation of the nucleus
accumbens shell. J. Neurosurg. 120, 997–1005 (2014).
Ward, M. P., Qing, K. Y., et al. A flexible platform for biofeedback-driven control and
personalization of electrical nerve stimulation therapy. IEEE Trans. Neural Syst.
Rehabil. Eng. (In Press). (2015).
Dryg, I. D., Ward, M. P., Qing, K. Y., et al. Magnetically inserted neural electrodes:
tissue response and functional lifetime. IEEE Trans. Neural Syst. Rehabil. Eng.
(Accepted). (2015).

Patents
Irazoqui, P. P., Ward, M. P. & Qing, K. Y. Burst pulse tissue stimulation method and
apparatus. (2014, provisional).*
* Qing, K. Y. should be first inventor. A full patent is currently being prepared.

